

05.05.2021

09:00 - 20:00 **Type: ePoster session** **On-Demand ePoster Display**  
**Title: ePoster Display Session**

09:00 - 09:00 **Biomarkers and translational research and precision medicine**

09:00 - 09:00 **5P - First clinical validation of the physical biomarker based on the nanomechanical tissue profiling in breast cancer for prediction of treatment outcome in a neoadjuvant therapy setting**

R. Burian, ARTIDIS AG, Basel, CH

09:00 - 09:00 **6P - 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/ HER2-negative breast cancer**

H. Dar<sup>1</sup>, A. Johansson<sup>1</sup>, A. Nordensköld<sup>2</sup>, A. Iftimi<sup>3</sup>, C. Yau<sup>4</sup>, G. Perez-Tenorio<sup>5</sup>, C. Benz<sup>4</sup>, B. Nordenskjöld<sup>5</sup>, O. Stål<sup>5</sup>, L. Esserman<sup>4</sup>, T. Fornander<sup>1</sup>, L. Lindström<sup>1</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Institute of Clinical Sciences, Gothenburg, SE, <sup>3</sup>University of Valencia, Valencia, ES, <sup>4</sup>University of California San Francisco, San Francisco, US, <sup>5</sup>Linköping University, Linköping, SE

09:00 - 09:00 **7P - An optimized Breast Cancer Index node-positive (BCIN+) prognostic model for late distant recurrence in patients with hormone receptor-positive (HR+) node-positive breast cancer**

G.-J. Liefers<sup>1</sup>, I. Noordhoek<sup>2</sup>, Y. Zhang<sup>3</sup>, D. Sgroi<sup>4</sup>, H. Putter<sup>1</sup>, K. Treuner<sup>3</sup>, J. Wong<sup>3</sup>, E. Meershoek-Klein Kranenbarg<sup>1</sup>, M. Duijm-De Carpentier<sup>1</sup>, C. Van De Velde<sup>5</sup>, C. Schnabel<sup>3</sup>, <sup>1</sup>Leiden University Medical Center, Leiden, NL, <sup>2</sup>Leids Universitair Medisch Centrum (LUMC), Leiden, NL, <sup>3</sup>Biotheranostics, Inc., San Diego, US, <sup>4</sup>Massachusetts General Hospital, Boston, US, <sup>5</sup>Prof. Cornelis van de Velde, Amsterdam, NL

09:00 - 09:00 **8P - Mutational analysis of circulating tumor DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): results from the TREnd trial.**

L. Malorni<sup>1</sup>, D. Romagnoli<sup>1</sup>, M. Benelli<sup>1</sup>, F. Galardi<sup>1</sup>, C. Biagioni<sup>1</sup>, G. Curigliano<sup>2</sup>, A. Minisini<sup>3</sup>, E. Moretti<sup>1</sup>, E. Risi<sup>1</sup>, F. De Luca<sup>1</sup>, A. McCartney<sup>4</sup>, A. Di Leo<sup>1</sup>, L. Biganzoli<sup>1</sup>, I. Migliaccio<sup>1</sup>, <sup>1</sup>Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, IT, <sup>4</sup>Monash Univeristy, Melbourne, AU

09:00 - 09:00 **9P - BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumor BRCA1 mutation**

Y. Wang<sup>1</sup>, E. Rosenberg<sup>2</sup>, G. Dackus<sup>3</sup>, A. Broeks<sup>2</sup>, S. Cornelissen<sup>2</sup>, P. Van Diest<sup>3</sup>, M. Hauptmann<sup>4</sup>, N. Ter Hoeve<sup>3</sup>, V. De Jong<sup>1</sup>, K. Jozwiak<sup>4</sup>, E. Koop<sup>5</sup>, P. Nederlof<sup>1</sup>, M. Opdam<sup>1</sup>, S. Siesling<sup>6</sup>, N. Stathonikos<sup>3</sup>, A. Voogd<sup>7</sup>, W. Vreuls<sup>8</sup>, M. Kok<sup>9</sup>, S. Linn<sup>1</sup>, M. Schmidt<sup>2</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-

AVL), Amsterdam, NL, <sup>3</sup>University Medical Center Utrecht, Utrecht, NL, <sup>4</sup>Brandenburg Medical School Theodor Fontane, Brandenburg, DE, <sup>5</sup>Gelre Ziekenhuizen, Apeldoorn, NL, <sup>6</sup>Netherlands Comprehensive Cancer Organization, Utrecht, NL, <sup>7</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>8</sup>Canisius Wilhelmina Ziekenhuis, Nijmegen, NL, <sup>9</sup>Netherlands Cancer Institute, Amsterdam, NL

- 09:00 - 09:00 **10P - The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers**  
N. Fusco<sup>1</sup>, E. Sajjadi<sup>1</sup>, K. Venetis<sup>1</sup>, M. Invernizzi<sup>2</sup>, D. Gambini<sup>3</sup>, C. Blundo<sup>3</sup>, L. Runza<sup>3</sup>, S. Ferrero<sup>4</sup>, E. Guerini Rocco<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>University of Eastern Piedmont, Novara, IT, <sup>3</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, IT, <sup>4</sup>University of Milan, Milan, IT
- 09:00 - 09:00 **11P - A Breast Cancer Index (BCI) prognostic model for N0 HR+ breast cancer optimized for late distant recurrence**  
J. Bartlett<sup>1</sup>, Y. Zhang<sup>2</sup>, I. Ahmed<sup>3</sup>, K. Treuner<sup>2</sup>, T. Piper<sup>4</sup>, S. Pirrie<sup>3</sup>, A. Brufsky<sup>5</sup>, D. Sgroi<sup>6</sup>, C. Schnabel<sup>2</sup>, D. Rea<sup>7</sup>, <sup>1</sup>Ontario Institute of Cancer Research, Ontario, CA, <sup>2</sup>Biotheranostics, Inc., San Diego, US, <sup>3</sup>University of Birmingham, Birmingham, GB, <sup>4</sup>University of Edinburgh, Edinburgh, GB, <sup>5</sup>Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>6</sup>Massachusetts General Hospital, Boston, US, <sup>7</sup>The University of Birmingham - Institute for Cancer Studies, Birmingham, GB
- 09:00 - 09:00 **12P - The RODILIA pilot study for molecular screening of patients with metaplastic breast cancer**  
M. Silvestri<sup>1</sup>, A. Vingiani<sup>2</sup>, L. De Cecco<sup>1</sup>, A. Belfiore<sup>3</sup>, E. Ortolan<sup>1</sup>, S. Veneroni<sup>1</sup>, A. Trama<sup>1</sup>, V. Cappelletti<sup>1</sup>, G. Pruneri<sup>3</sup>, S. Di Cosimo<sup>4</sup>, <sup>1</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, MILANO, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori Department of Pathology, IRCCS Fondazione Istituto Nazionale Tumori and University of Milan, MILANO, IT, <sup>3</sup>IRCCS Fondazione Istituto Nazionale dei Tumori and University of Milan, MILANO, IT, <sup>4</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT
- 09:00 - 09:00 **13P - Comparison study of different programmed death-ligand 1 (PD-L1) assays, readers and scoring methods in triple-negative breast cancer (TNBC)**  
A. Noske<sup>1</sup>, D.-C. Wagner<sup>2</sup>, K. Schwamborn<sup>3</sup>, S. Foersch<sup>2</sup>, K. Steiger<sup>1</sup>, M. Kiechle<sup>4</sup>, S. Karapetyan<sup>1</sup>, D. Oettler<sup>5</sup>, A. Hapfelmeier<sup>1</sup>, W. Roth<sup>2</sup>, W. Weichert<sup>3</sup>, <sup>1</sup>TUM - Technical University of Munich, Munich, DE, <sup>2</sup>Johannes Gutenberg University Mainz, Mainz, DE, <sup>3</sup>Technische Universität München-Institute of Pathology, Munich, DE, <sup>4</sup>Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE, <sup>5</sup>MSD Sharp & Dohme GmbH, Haar, DE
- 09:00 - 09:00 **14P - Immunomodulatory effect of denosumab in early breast cancer: preliminary results of a randomized window-opportunity clinical trial D-Biomark (NCT03691311).**  
A. Vethencourt<sup>1</sup>, E. Trinidad<sup>2</sup>, C. Gómez Aleza<sup>2</sup>, S. Pernas Simon<sup>1</sup>, A. Petit<sup>3</sup>, T. Soler<sup>3</sup>, A. Urruticoechea<sup>4</sup>, A. Gumà Martinez<sup>3</sup>, A. García-Tejedor<sup>5</sup>, M.J. Pla<sup>3</sup>, C. Capó<sup>6</sup>, M. Gil Gil<sup>1</sup>, A. Stradella<sup>7</sup>, A. Fernández<sup>1</sup>, S. Recalde Penabad<sup>8</sup>, M. Cejuela<sup>9</sup>, S. Vazquez<sup>1</sup>, A. Iserte<sup>1</sup>, C.

Falo<sup>1</sup>, E. Gonzalez-Suarez<sup>10</sup>, <sup>1</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>2</sup>IDIBELL FUNDACION PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE, Barceloma, ES, <sup>3</sup>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, <sup>4</sup>Private Practice - Urruticoechea, Barcelona, ES, <sup>5</sup>Institut Català D'Oncologia, Barcelona, ES, <sup>6</sup>Hospital de Viladecans, Viladecans, ES, <sup>7</sup>ICO - Institut Catala d'Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, ES, <sup>8</sup>Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, <sup>9</sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, ES, <sup>10</sup>CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES

- 09:00 - 09:00 **15P - The combined influence of receptor subtype, grade and TN status on breast cancer survival in recently treated women with non-metastatic disease in Norway**  
A. Johansson<sup>1</sup>, C. Trewin<sup>2</sup>, I. Fredriksson<sup>3</sup>, K. Reinertsen<sup>4</sup>, H. Russnes<sup>4</sup>, G. Ursin<sup>2</sup>,  
<sup>1</sup>Karolinska Institutet, Huddinge, SE, <sup>2</sup>Cancer Registry of Norway, Oslo, NO, <sup>3</sup>Karolinska Institutet, Stockholm, SE, <sup>4</sup>Oslo University Hospital, Oslo, NO
- 09:00 - 09:00 **16P - Understanding the biologic determinants of ribociclib efficacy in breast cancer**  
F. Brasó-Maristany<sup>1</sup>, M. Palafox<sup>2</sup>, L. Monserrat<sup>2</sup>, M. Bellet<sup>2</sup>, M. Oliveira<sup>2</sup>, M. Capelán<sup>2</sup>, P. Galván<sup>1</sup>, D. Martínez<sup>1</sup>, N. Chic<sup>1</sup>, C. Viaplana<sup>2</sup>, R. Dienstmann<sup>3</sup>, P. Nuciforo<sup>2</sup>, C. Saura Manich<sup>4</sup>, A. Prat<sup>5</sup>, V. Serra<sup>3</sup>, <sup>1</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>2</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>3</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>4</sup>Vall d' Hebron University Hospital Institut d'Oncologia, Barcelona, ES, <sup>5</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 09:00 - 09:00 **17P - Impact of body mass index (BMI) on prognostic and predictive value of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative breast cancer (TNBC): a pooled analysis of six neoadjuvant trials.**  
J. Furlanetto<sup>1</sup>, C. Denkert<sup>2</sup>, M. Untch<sup>3</sup>, B. Sinn<sup>4</sup>, B. Lederer<sup>1</sup>, A. Schneeweiss<sup>5</sup>, V. Mueller<sup>6</sup>, M. Van Mackelenbergh<sup>7</sup>, E. Stickeler<sup>8</sup>, P.A. Fasching<sup>9</sup>, C. Schem<sup>10</sup>, T. Karn<sup>11</sup>, F. Marmé<sup>12</sup>, V. Nekljudova<sup>1</sup>, S. Loibl<sup>13</sup>, <sup>1</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>2</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>3</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>4</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>5</sup>Nationales Centrum für Tumorerkrankungen, Heidelberg, DE, <sup>6</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>7</sup>7. Universitätsklinikum Schleswig-Holstein, Schleswig-Holstein, DE, <sup>8</sup>Uniklinik RWTH Aachen, Aachen, DE, <sup>9</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>10</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>11</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>12</sup>UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>13</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE
- 09:00 - 09:00 **18P - Age-related breast cancer gene expression signature with strong prognostic value**  
L. Ingebriktzen<sup>1</sup>, E. Wik<sup>1</sup>, L. Akslen<sup>2</sup>, <sup>1</sup>University of Bergen, Bergen, NO, <sup>2</sup>Haukeland Univeristy Hospital, Bergen, NO
- 09:00 - 09:00 **19P - A dichotomous oncogenic role of the splicing factor SF3A3 in MYC-driven**

**Triple Negative Breast Cancer.**

A. Bosch<sup>1</sup>, M. Cieřla<sup>1</sup>, P. Cao Thi Ngoc<sup>1</sup>, S. Mutukumar<sup>1</sup>, G. Honeth<sup>1</sup>, J. Staaf<sup>1</sup>, D. Incarnato<sup>2</sup>, K. Pietras<sup>1</sup>, C. Bellodi<sup>1</sup>, <sup>1</sup>Lund University, Lund, SE, <sup>2</sup>University of Groningen, Groningen, NL

09:00 - 09:00 **20P - Is evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutational status on circulating tumor DNA (ctDNA) by liquid biopsy ready for prime-time? A systematic review and an individual patient meta-analysis**

L. Castellana<sup>1</sup>, V. Gristina<sup>2</sup>, A. Galvano<sup>2</sup>, M. La Mantia<sup>2</sup>, L. Insalaco<sup>2</sup>, N. Barraco<sup>2</sup>, S. Cutaia<sup>2</sup>, F. Iacono<sup>2</sup>, G. Santanelli<sup>2</sup>, A. Cucinella<sup>2</sup>, G. Madonia<sup>2</sup>, M.R. Ricciardi<sup>2</sup>, M.C. Lisanti<sup>2</sup>, V. Calò<sup>2</sup>, M. Castiglia<sup>2</sup>, A. Perez<sup>2</sup>, S. Cusenza<sup>2</sup>, S. Rizzo<sup>2</sup>, A. Russo<sup>2</sup>, V. Bazan<sup>2</sup>, <sup>1</sup>AOUP Paolo Giaccone, Palermo, IT, <sup>2</sup>AOU Policlinico "Paolo Giaccone", Palermo, IT

09:00 - 09:00 **21P - BACH1 and HIF1 $\alpha$  predict response to neoadjuvant nab-paclitaxel (nP) treatment in early breast cancer (BC)**

V. Vladimirova<sup>1</sup>, A. Schneeweiss<sup>2</sup>, C. Jackisch<sup>3</sup>, K. Weber<sup>1</sup>, C. Denkert<sup>4</sup>, S. Schmatloch<sup>5</sup>, T. Karn<sup>6</sup>, P.A. Fasching<sup>7</sup>, S. Braun<sup>8</sup>, C. Szeto<sup>9</sup>, B. Sinn<sup>10</sup>, M. Van Mackelenbergh<sup>11</sup>, C. Schem<sup>12</sup>, E. Stickeler<sup>13</sup>, P. Soon-Shiong<sup>9</sup>, F. Marmé<sup>14</sup>, V. Mueller<sup>15</sup>, M. Untch<sup>16</sup>, V. Nekljudova<sup>17</sup>, S. Loibl<sup>18</sup>, <sup>1</sup>GBG, Neu-Isenburg, DE, <sup>2</sup>Nationales Centrum für Tumorerkrankungen, Heidelberg, DE, <sup>3</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>4</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>5</sup>Elisabeth-Krankenhaus Kassel, Kassel, DE, <sup>6</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>7</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>8</sup>Sana Klinikum Offenbach, Offenbach am Main, DE, <sup>9</sup>ImmunityBio Inc, Santa Cruz, US, <sup>10</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>11</sup>Universitätsklinikum Schleswig-Holstein, Kiel, DE, <sup>12</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>13</sup>Uniklinik RWTH Aachen, Aachen, DE, <sup>14</sup>UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>15</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>16</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>17</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>18</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

09:00 - 09:00 **22P - HER2-low vs HER2-zero metastatic breast carcinoma: a clinical and genomic descriptive analysis.**

R. Sanchez Bayona<sup>1</sup>, A. Luna<sup>2</sup>, P. Tolosa<sup>1</sup>, A. Sánchez De Torre<sup>1</sup>, A. Castelo<sup>1</sup>, M. Marín<sup>3</sup>, C. García<sup>1</sup>, V. Boni<sup>4</sup>, E. Bernal Hertfelder<sup>5</sup>, E. Vega<sup>6</sup>, B. Rojas<sup>6</sup>, R. Bratos<sup>7</sup>, M. Martínez<sup>1</sup>, Á. Díaz Bermejo<sup>1</sup>, L. Lema<sup>1</sup>, L. Manso<sup>1</sup>, E. Ciruelos<sup>1</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>HM Sanchinarro, Madrid, ES, <sup>3</sup>Universidad Complutense, Madrid, ES, <sup>4</sup>Hospital Madrid Norte San Chinarro - Centro Integral Oncológico Clara Campal, Madrid, ES, <sup>5</sup>Emergency Hospital Universitario de Móstoles, Mostoles, ES, <sup>6</sup>HM CIOCC, Madrid, ES, <sup>7</sup>HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES

09:00 - 09:00 **23P - CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): a retrospective analysis of real-world data**

O. Martínez-Sáez<sup>1</sup>, P. Tolosa<sup>2</sup>, A. Sánchez De Torre<sup>2</sup>, T. Pascual<sup>3</sup>, F. Brasó-Maristany<sup>4</sup>, A. Rodriguez Hernandez<sup>3</sup>, L. Parrilla<sup>2</sup>, A.M. Roncero<sup>2</sup>, Y. Ruano<sup>2</sup>, N. Chic<sup>4</sup>, F. Schettini<sup>5</sup>, J.C. Laguna<sup>3</sup>, E. Sanfeliu Torres<sup>1</sup>, B. Gonzalez-Farre<sup>1</sup>, M. Vidal<sup>1</sup>, B. Adamo<sup>3</sup>, M.C. Guillen

Sacoto<sup>6</sup>, M. Muñoz<sup>1</sup>, A. Prat<sup>3</sup>, E. Ciruelos<sup>2</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>4</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>5</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>6</sup>IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES

- 09:00 - 09:00 **24P - Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European Breast Cancer clinicians - The PROCURE project.**  
G. Curigliano<sup>1</sup>, F. Cardoso<sup>2</sup>, M. Gnant<sup>3</sup>, N. Harbeck<sup>4</sup>, A.-V. Lænkholm<sup>5</sup>, F. Penault-Llorca<sup>6</sup>, A. Prat<sup>7</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>Champalimaud Foundation Cancer Center, Lisbon, PT, <sup>3</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>4</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>5</sup>Zealand University Hospital, Roskilde, DK, <sup>6</sup>Jean Perrin Center, Clermont-Ferrand, FR, <sup>7</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 09:00 - 09:00 **25P - Investigation of TLR4 and pSTAT3 expression on circulating tumor cells (CTCs) in patients with metastatic breast cancer (mBC)**  
M.A. Papadaki<sup>1</sup>, C.A. Apostolopoulou<sup>1</sup>, A. Monastirioti<sup>2</sup>, D. Aggouraki<sup>1</sup>, C. Papadaki<sup>3</sup>, K. Michaelidou<sup>1</sup>, D. Mavroudis<sup>4</sup>, S. Agelaki<sup>3</sup>, <sup>1</sup>University of Crete, Heraklion, GR, <sup>2</sup>University of Crete - School of Medicine, Heraklion, GR, <sup>3</sup>University Hospital of Heraklion (PAGNI), Heraklion, GR, <sup>4</sup>University Hospital of Heraklion, Heraklion, GR
- 09:00 - 09:00 **26P - Characterization of low HER2 expressions in de-novo metastatic breast cancer**  
P. Tarantino<sup>1</sup>, E. Nicolò<sup>2</sup>, P. Zagami<sup>3</sup>, F. Giugliano<sup>1</sup>, P. Trillo Aliaga<sup>3</sup>, E. Crimini<sup>1</sup>, C. Corti<sup>1</sup>, J. Uliano<sup>2</sup>, S. Morganti<sup>3</sup>, L. Mazarella<sup>1</sup>, C. Criscitiello<sup>1</sup>, A. Esposito<sup>2</sup>, G. Curigliano<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup>European Institute of Oncology, Milan, IT, <sup>3</sup>Istituto Europeo di Oncologia, Milan, IT
- 09:00 - 09:00 **27P - MiR-221/222 may enhance epithelial-mesenchymal transition and tamoxifen resistance by down-regulating GATA3**  
Y.-K. Liang<sup>1</sup>, Q. Xie<sup>2</sup>, Z.-H. Wang<sup>1</sup>, W. Wang<sup>3</sup>, Z.-M. Xie<sup>4</sup>, X.-F. Xiao<sup>1</sup>, D. Zeng<sup>5</sup>, H. Lin<sup>6</sup>, <sup>1</sup>The First Affiliated Hospital of Shantou University Medical College, Shantou, CN, <sup>2</sup>Shantou University Medical College, Shantou, CN, <sup>3</sup>Cancer Hospital of Shantou University, Shantou, CN, <sup>4</sup>Cancer Hospital of Shantou University Medical College, Shantou, CN, <sup>5</sup>Shantou University Medical College, Shantou, CN, <sup>6</sup>The First Affiliated Hospital of Shantou University Medical College, Shantou, CN
- 09:00 - 09:00 **28P - EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy**  
J. Leichsenring<sup>1</sup>, V. Vladimirova<sup>2</sup>, C. Solbach<sup>3</sup>, T. Karn<sup>3</sup>, B. Ataseven<sup>4</sup>, B. Sinn<sup>5</sup>, J. Barinoff<sup>6</sup>, V. Mueller<sup>7</sup>, J.-U. Blohmer<sup>6</sup>, C. Schem<sup>8</sup>, K. Engels<sup>9</sup>, F. Marmé<sup>10</sup>, A. Fissler-Eckhoff<sup>11</sup>, P.A. Fasching<sup>12</sup>, E. Stickeler<sup>13</sup>, M. Van Mackelenbergh<sup>14</sup>, C. Denkert<sup>15</sup>, A. Stenzinger<sup>1</sup>, S. Loibl<sup>16</sup>, S. Gröschel<sup>17</sup>, <sup>1</sup>Universitätsklinikum Heidelberg, Heidelberg, DE, <sup>2</sup>GBG, Neu-Isenburg, DE, <sup>3</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>4</sup>Kliniken Essen-Mitte and Universitätsklinikum

München (LMU), Essen and München, DE, <sup>5</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>6</sup>St. Gertrauden-Krankenhaus, Berlin, DE, <sup>7</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>8</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>9</sup>Center for Pathology, Cytology and Molecular Pathology, Neuss, Neuss, DE, <sup>10</sup>UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>11</sup>Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, DE, <sup>12</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>13</sup>Uniklinik RWTH Aachen, Aachen, DE, <sup>14</sup>Universitätsklinikum Schleswig-Holstein, Kiel, DE, <sup>15</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>16</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, <sup>17</sup>Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, DE

- 09:00 - 09:00 **29P - Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer**
- M. Bos<sup>1</sup>, S. Lam<sup>2</sup>, J. Helmijr<sup>3</sup>, C. Beaufort<sup>1</sup>, A. Jager<sup>4</sup>, J. Martens<sup>1</sup>, E. Boven<sup>5</sup>, M. Jansen<sup>6</sup>, S. Sleijfer<sup>4</sup>, <sup>1</sup>Erasmus MC Cancer Institute, Rotterdam, NL, <sup>2</sup>Amsterdam UMC, Vrije Universiteit Amsterdam/Cancer Center Amsterdam, Amsterdam, NL, <sup>3</sup>Erasmus MC Cancer Institute, Amsterdam, NL, <sup>4</sup>Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, <sup>5</sup>Vrije University Medical Centre (VUMC), Amsterdam, NL, <sup>6</sup>Erasmus University Medical Center, Rotterdam, NL
- 09:00 - 09:00 **30P - Expression Signature of Let-7a, miR-34a and miR-486-5p in Young Triple Negative Breast Cancer Patients Overexpressing PDL1: A Step towards Precision Immuno-oncology**
- C. Kiriacos<sup>1</sup>, M. Khedr<sup>1</sup>, M. Tadros<sup>1</sup>, H. Hafez<sup>2</sup>, R. Youness<sup>3</sup>, <sup>1</sup>German University in Cairo, Cairo, EG, <sup>2</sup>Faculty of Medicine, Kasr El-Ainy, Cairo University, Cairo, EG, <sup>3</sup>GUC - German University in Cairo, New Cairo, EG
- 09:00 - 09:00 **31P - Association between breast cancer protein truncating variants and febrile neutropenia breast cancer patients treated with taxane or anthracycline chemotherapy in Singapore**
- S.S. Ong<sup>1</sup>, P.J. Ho<sup>1</sup>, A. Khng<sup>1</sup>, G.H. Lim<sup>2</sup>, S.H. Lim<sup>2</sup>, S.G.W. Ow<sup>3</sup>, J.S. Pang<sup>2</sup>, B. Kiat Tee Tan<sup>4</sup>, E.Y. Tan<sup>5</sup>, S.M. Tan<sup>6</sup>, V. Kiak Mien Tan<sup>4</sup>, F.Y. Wong<sup>7</sup>, J. Li<sup>1</sup>, M. Hartman<sup>8</sup>, <sup>1A</sup>\*STAR - Genome Institute of Singapore (GIS), Singapore, SG, <sup>2</sup>KK Women's and Children's Hospital, Singapore, SG, <sup>3</sup>National University Cancer Institute, Singapore, Singapore, SG, <sup>4</sup>Singapore General Hospital, Singapore, SG, <sup>5</sup>Tan Tock Seng Hospital, Singapore, SG, <sup>6</sup>Changi General Hospital, Singapore, SG, <sup>7</sup>National Cancer Centre Singapore, Singapore, SG, <sup>8</sup>National University of Singapore and National University Health System, Singapore, SG
- 09:00 - 09:00 **32P - PIK3CA exon 9 and 20 mutations in early luminal breast cancer. Case series and review of the literature.**
- I. Betancor Fernández<sup>1</sup>, C. González García<sup>2</sup>, A. Ramos-Navas<sup>2</sup>, E. Salido Ruiz<sup>3</sup>, <sup>1</sup>Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, <sup>2</sup>Hospital Universitario de Canarias, San Cristóbal de La Laguna, ES, <sup>3</sup>Hospital Universitario de Canarias, San Cristóbal de la Laguna, ES
- 09:00 - 09:00 **33P - Epigenetics biomarkers ID1, HOXB2 and ATOH8 could predict response to chemotherapy and prognosis in early breast cancer**

V. Quiroga Garcia<sup>1</sup>, S. Moran<sup>2</sup>, C. Queralt<sup>1</sup>, S. Cabrero<sup>3</sup>, A. Bernat<sup>4</sup>, A. Ferrando Diez<sup>5</sup>, L. Perez<sup>5</sup>, B. Cirauqui Cirauqui<sup>1</sup>, E. Felip<sup>1</sup>, I. Teruel-Garcia<sup>1</sup>, M. Romeo Marin<sup>6</sup>, A. Pous<sup>5</sup>, E. Castellà<sup>5</sup>, A. Martinez-Cardús<sup>4</sup>, M. Margeli<sup>7</sup>, <sup>1</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>2</sup>Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Hospitalet, ES, <sup>3</sup>Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, ES, <sup>4</sup>Badalona Applied Research Group in Oncology (B-ARGO), Badalona, ES, <sup>5</sup>Hospital Universitario Germans Trias i Pujol, Badalona, ES, <sup>6</sup>Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, Badalona, ES, <sup>7</sup>ICO-Badalona. Hospital Germans Trias i Pujol. GEICAM, Spanish Breast Cancer Group, Badalona, ES

09:00 - 09:00 **34P - New pathogenic germline mutation in ATM gene in Khakass breast cancer patients**

P. Gervas<sup>1</sup>, N. Cherdyntseva<sup>2</sup>, <sup>1</sup>Tomskogo Nimits Cancer Research Institute, Tomsk, RU, <sup>2</sup>Tomsk National Research Medical Center, Russian Academy of Sciences Cancer Research Institute, Tomsk, RU

09:00 - 09:00 **35P - Prognostic impact of Cytotoxic CD4 T cells (CD4 CTL) in tumor immune microenvironment of breast cancer patients**

K. Shohdy<sup>1</sup>, D. Almeldin<sup>2</sup>, R. Ghaly<sup>1</sup>, L. Kassem<sup>2</sup>, O. Pagani<sup>3</sup>, <sup>1</sup>Kasr Al Ainy School of Medicine - Cairo University - Faculty of Medicine, Cairo, EG, <sup>2</sup>Cairo University - Faculty Of Medicine, Cairo, EG, <sup>3</sup>HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH

09:00 - 09:00 **36P - The association between tri-nucleotide-repeat containing 9 (TNRC9) /LOC643714 genetic variations and breast cancer in Egyptian females**

A. Alhanafy<sup>1</sup>, M. El-Shafie<sup>2</sup>, A. Abdu Allah<sup>2</sup>, S. Rizk<sup>2</sup>, M. Habieb<sup>2</sup>, <sup>1</sup>MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, <sup>2</sup>Faculty of Medicine - Menoufia University, sheben elkom, EG

09:00 - 09:00 **37P - Genetic alteration in KLK5 associated with individual mode of breast cancer invasion**

N. Novikov<sup>1</sup>, A. Fokin<sup>1</sup>, S. Zolotaryova<sup>1</sup>, A. Kiselev<sup>1</sup>, A. Gautreau<sup>2</sup>, E. Denisov<sup>3</sup>, <sup>1</sup>Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RU, <sup>2</sup>Ecole Polytechnique, Palaseau, FR, <sup>3</sup>Tomsk Cancer Research Institute RAMS, Tomsk, RU

09:00 - 09:00 **38P - Triple negative breast cancers with expression of Glucocorticoid receptor in immune cells show better prognosis**

J. Prabhu<sup>1</sup>, S. Patil<sup>1</sup>, S. Rajarajan<sup>1</sup>, A. Ce<sup>1</sup>, M. Nair<sup>1</sup>, A. Alexander<sup>1</sup>, R. Ramesh<sup>2</sup>, S. Bs<sup>3</sup>, T. Sridhar<sup>1</sup>, <sup>1</sup>St Johns Research Institute, Bangalore, IN, <sup>2</sup>St Johns Medical College Hospital, Bangalore, IN, <sup>3</sup>Shankara Cancer Hospital & Research Centre, Bangalore, IN

09:00 - 09:00 **39P - Applicability of a pathology-based combined model NOLUS (NON-LUMINAL Score) in HR+/HER2- early breast cancer patients treated at a tertiary referral center in México**

A. Valenzuela-Vidales<sup>1</sup>, A. Armengol-Alonso<sup>2</sup>, <sup>1</sup>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, MX, <sup>2</sup>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, CDMX, MX

- 09:00 - 09:00 **40TiP - SOLTI-1802 ONAWA Trial: A Window of Opportunity Trial of Onapristone (ONA) in Postmenopausal Women with Estrogen and Progesterone Receptor-Positive/HER2-negative (ER+/PgR+/HER2-) Early Breast Cancer (EBC)**
- M. Bellet<sup>1</sup>, S. Morales Murillo<sup>2</sup>, A. Gasol Cudos<sup>2</sup>, K. Amillano<sup>3</sup>, N. Chic<sup>4</sup>, X. González-Farré<sup>5</sup>, P. Villagrasa<sup>6</sup>, J. Ferrero-Cafiero<sup>7</sup>, T. Pascual<sup>8</sup>, A. Prat<sup>8</sup>, C. Lange<sup>9</sup>, C. Saura Manich<sup>10</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>2</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>3</sup>Hospital Universitari Sant Joan de Reus, Reus, Spain, Reus, ES, <sup>4</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>5</sup>Hospital General de Catalunya, Sant Cugat del Vallés, ES, <sup>6</sup>SOLTI Breast Cancer Research Group, Barcelona, ES, <sup>7</sup>SOLTI HQ, Barcelona, ES, <sup>8</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>9</sup>Masonic Cancer Center, University of Minnesota, Minneapolis, US, <sup>10</sup>Vall d'Hebron University Hospital Institut d'Oncologia, Barcelona, ES
- 09:00 - 09:00 **Early Breast cancer: Adjuvant therapy**
- 09:00 - 09:00 **45P - Long-term Efficacy of Neratinib in HER2-Positive Early-Stage Breast Cancer: Overall Survival and Central Nervous System Outcomes from the Phase 3 ExteNET Trial**
- A. Chan<sup>1</sup>, B. Moy<sup>2</sup>, J. Mansi<sup>3</sup>, M. Gnant<sup>4</sup>, C. Barrios<sup>5</sup>, R. Separovic<sup>6</sup>, A. Guerrero-Zotano<sup>7</sup>, I. Gore<sup>8</sup>, J. Smith<sup>9</sup>, R. Bryce<sup>10</sup>, F. Xu<sup>10</sup>, A. Wong<sup>11</sup>, M. Martin<sup>12</sup>, F.A. Holmes<sup>13</sup>, <sup>1</sup>Breast Cancer Research Centre-WA, Perth & Curtin University, Nedlands, AU, <sup>2</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>3</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>4</sup>Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, <sup>5</sup>Centro de Hematologia Oncologia E Transplante, Porto Alegre, BR, <sup>6</sup>University Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR, <sup>7</sup>Fundación Instituto Valenciano de Oncología (FIVO); GEICAM, Spanish Breast Cancer Group, Valencia, ES, <sup>8</sup>Alabama Oncology, Birmingham, US, <sup>9</sup>Compass Oncology, Portland, US, <sup>10</sup>Puma Biotechnology, Inc., Los Angeles, US, <sup>11</sup>Puma Biotechnology Inc., Los Angeles, US, <sup>12</sup>Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense de Madrid, Madrid, ES, <sup>13</sup>Texas Oncology, US Oncology, Houston, US
- 09:00 - 09:00 **46P - Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Safety results from the adjuvant phase of the randomised, open-label, multicentre phase 3 (neo)adjuvant FeDeriCa study**
- S.-A. Im<sup>1</sup>, A. Tan<sup>2</sup>, A. Mattar<sup>3</sup>, R. Colomer<sup>4</sup>, D. Stroyakovskii<sup>5</sup>, Z. Nowecki<sup>6</sup>, M. De Laurentiis<sup>7</sup>, J.-Y. Pierga<sup>8</sup>, K.H. Jung<sup>9</sup>, C. Schem<sup>10</sup>, C. Aguila<sup>11</sup>, T. Badovinac Crnjevic<sup>11</sup>, S. Heeson<sup>12</sup>, M. Shivhare<sup>12</sup>, A. Alexandrou<sup>12</sup>, E. Restuccia<sup>11</sup>, C. Jackisch<sup>13</sup>, <sup>1</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>2</sup>Levine Cancer Institute, Atrium Health, Charlotte, US, <sup>3</sup>Hospital Pérola Byington, São Paulo, BR, <sup>4</sup>Division of Medical Oncology, Madrid, ES, <sup>5</sup>City Clinical Oncology Hospital 62, Moscow, RU, <sup>6</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>7</sup>Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Napoli, IT, <sup>8</sup>Institut Curie, Paris, FR, <sup>9</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>10</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>11</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>12</sup>Roche Products Limited, Welwyn Garden City, GB, <sup>13</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE

- 09:00 - 09:00 **47P - The impact of endocrine therapy and chemotherapy on quality of life 5 years after a breast cancer diagnosis: VICAN5 Survey**  
V. Memoli<sup>1</sup>, D. Rey<sup>1</sup>, S. Lauzier<sup>2</sup>, J. Mancini<sup>1</sup>, A.-D. Bouhnik<sup>3</sup>, <sup>1</sup>UMR 1252 SESSTIM AMU, INSERM, IRD, Marseille, FR, <sup>2</sup>Population Health and Optimal Health Practices research Axis, Quebec, CA, <sup>3</sup>SESSTIM-INSERMUMR912-IRD-AMU, Marseille, FR
- 09:00 - 09:00 **48P - Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE**  
Y.-S. Yap<sup>1</sup>, S.-B. Kim<sup>2</sup>, J. Chiu<sup>3</sup>, E. Lim<sup>4</sup>, R. Broom<sup>5</sup>, Z. Liu<sup>6</sup>, Y. Sagara<sup>7</sup>, T.-Y. Chao<sup>8</sup>, S. Sherwood<sup>9</sup>, R. Mcnaughton<sup>9</sup>, R. Wei<sup>9</sup>, M. Toi<sup>10</sup>, <sup>1</sup>National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>Queen Mary Hospital, Hong Kong, HK, <sup>4</sup>St Vincent's Hospital and Garvan Institute of Medical Research, Sydney, AU, <sup>5</sup>Auckland City Hospital, Auckland, NZ, <sup>6</sup>Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Social Medical Corporation Hakuai Sagara Hospital, Kagoshima, JP, <sup>8</sup>Taipei Medical University - Shuang Ho Hospital, New Taipei City, TW, <sup>9</sup>Eli Lilly, Indianapolis, US, <sup>10</sup>Kyoto University-Graduate school of medicine, Kyoto, JP
- 09:00 - 09:00 **49P - Socioeconomic status and survivorship in premenopausal breast cancer patients: A population-based cohort study**  
C. Hjorth<sup>1</sup>, D. Cronin-Fenton<sup>2</sup>, P. Damkier<sup>3</sup>, T. Lash<sup>4</sup>, H. Sørensen<sup>2</sup>, B. Ejlersen<sup>5</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Aarhus University Hospital, Aarhus N, DK, <sup>3</sup>Odense University Hospital, Odense, DK, <sup>4</sup>Rollins School of Public Health, Emory University, Atlanta, US, <sup>5</sup>Rigshospitalet, Glostrup, DK
- 09:00 - 09:00 **50P - Early breast cancer in women aged 35 years or younger: a French population-based case control-matched analysis**  
O. Dufour<sup>1</sup>, G. Houvenaeghel<sup>2</sup>, J.-M. Classe<sup>3</sup>, M. Cohen<sup>4</sup>, C. Faure<sup>5</sup>, C. Mazouni<sup>6</sup>, M.-P. Chauvet<sup>7</sup>, E. Jouve<sup>8</sup>, E. Darai<sup>9</sup>, A.-S. Azuar<sup>10</sup>, P. Guimbergues<sup>11</sup>, A. Gonçalves<sup>2</sup>, A. De Nonneville<sup>2</sup>, <sup>1</sup>Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, <sup>2</sup>Institute Paoli Calmettes, Marseille, FR, <sup>3</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>4</sup>Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Surgical Oncology, CRCM, Marseille, France, Marseille, FR, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>Centre Oscar Lambret, Lille, FR, <sup>8</sup>Centre Claudius Regaud, Toulouse, FR, <sup>9</sup>Hôpital Tenon, Paris, FR, <sup>10</sup>Hôpital de Grasse, Grasse, FR, <sup>11</sup>Centre Jean Perrin, Clermont-Ferrand, FR
- 09:00 - 09:00 **51P - The development of a predictive model for risk results of the 70-gene signature**  
L. Slembrouck<sup>1</sup>, I. Sebastian<sup>2</sup>, A. Martinez<sup>2</sup>, I. Vanden Bempt<sup>3</sup>, H. Wildiers<sup>1</sup>, A. Smeets<sup>1</sup>, A.-S. Van Rompuy<sup>3</sup>, C. Weltens<sup>3</sup>, K. Punie<sup>1</sup>, E. Van Nieuwenhuysen<sup>3</sup>, S. Han<sup>3</sup>, I. Nevelsteen<sup>1</sup>, P. Neven<sup>1</sup>, G. Floris<sup>1</sup>, <sup>1</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>2</sup>KU Leuven, Leuven, BE, <sup>3</sup>University Hospitals Leuven, Leuven, BE
- 09:00 - 09:00 **52P - Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis**

S. Peleg Hasson, E. Shachar, M. Brezis, S. Shachar, I. Wolf, A. Sonnenblick, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

- 09:00 - 09:00 **53P - Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: subgroup analysis in breast cancer patients**
- R. Mahtani<sup>1</sup>, G. Lyman<sup>2</sup>, R. Rifkin<sup>3</sup>, D. Dale<sup>4</sup>, A. Brookhart<sup>5</sup>, S. Lewis<sup>6</sup>, L. Decosta<sup>7</sup>, T. Lawrence<sup>6</sup>, R. Belani<sup>6</sup>, J. Crawford<sup>8</sup>, <sup>1</sup>University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, <sup>2</sup>Fred Hutchinson Cancer Research Center, Seattle, US, <sup>3</sup>Research Rocky Mountain Cancer Centers, Denver, US, <sup>4</sup>University of Washington, Seattle, US, <sup>5</sup>Duke University, Durham, US, <sup>6</sup>Amgen Inc., Thousand Oaks, US, <sup>7</sup>Amgen Ltd., Uxbridge, GB, <sup>8</sup>Duke University School of Medicine, Durham, US
- 09:00 - 09:00 **54P - Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis**
- K. Harborg<sup>1</sup>, R. Zachariae<sup>1</sup>, J. Olsen<sup>1</sup>, M. Johannsen<sup>2</sup>, D. Cronin-Fenton<sup>3</sup>, H. Bøggild<sup>4</sup>, S. Borgquist<sup>1</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Aarhus University, Aarhus, DK, <sup>3</sup>Aarhus University Hospital, Aarhus N, DK, <sup>4</sup>Aalborg University, Aalborg, DK
- 09:00 - 09:00 **55P - Molecular Risk Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- EBC**
- H. Ni<sup>1</sup>, J. Kumbrink<sup>2</sup>, D. Mayr<sup>2</sup>, A. Seiler<sup>3</sup>, F. Hagemann<sup>4</sup>, T. Degenhardt<sup>1</sup>, S. Sagebiel<sup>2</sup>, R. Wuerstlein<sup>2</sup>, N. Harbeck<sup>3</sup>, T. Eggersmann<sup>5</sup>, <sup>1</sup>Hospital Munich Grosshadern - Ludwig-Maximilians-University (LMU), Munich, DE, <sup>2</sup>LMU Klinikum der Universität München, Munich, DE, <sup>3</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>4</sup>LMU - Klinikum der Universitaet München - Frauenklinik Maistrasse, Munich, DE, <sup>5</sup>LMU - Ludwig Maximilians University - Grosshadern, Munich, DE
- 09:00 - 09:00 **56P - The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer**
- Y. Bar<sup>1</sup>, K. Bar<sup>2</sup>, I. Itzhak<sup>3</sup>, C. Shitrit Niselbaum<sup>3</sup>, N. Dershowitz<sup>4</sup>, E. Shachar<sup>1</sup>, A. Weiss-Meilik<sup>4</sup>, O. Golan<sup>1</sup>, I. Wolf<sup>1</sup>, T. Menes<sup>5</sup>, A. Sonnenblick<sup>1</sup>, <sup>1</sup>Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, <sup>2</sup>The College of Management, Rishon LeZion, IL, <sup>3</sup>Tel-Aviv Sourasky Medical Center, Tel Aviv, IL, <sup>4</sup>Tel Aviv University, Tel Aviv, IL, <sup>5</sup>Chaim Sheba Medical Center, Tel-Hashomer , IL
- 09:00 - 09:00 **57P - The Level of Agreement among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer Pre and Post Oncotype DX result**
- A. Alkushi<sup>1</sup>, A. Omair<sup>1</sup>, A. Abusanad<sup>2</sup>, E. Masuadi<sup>3</sup>, G. Alamri<sup>3</sup>, N. Abdulhafiz<sup>1</sup>, A. Mohamed<sup>1</sup>, O. Abualkair<sup>4</sup>, <sup>1</sup>King Abdulaziz medical city of national guard, Riyadh, SA, <sup>2</sup>King Abdulaziz University, Jeddah, SA, <sup>3</sup>King Saud bin Abdulaziz University for Health Sciences, Riyadh, SA, <sup>4</sup>sulaiman alhabib hospital, Riyadh, SA
- 09:00 - 09:00 **58P - Cost-effectiveness Analysis of Trastuzumab Emtansine versus Trastuzumab for Chinese Patients with Residual Invasive HER2-Positive Early Breast Cancer**
- X. Guan<sup>1</sup>, H.-C. Li<sup>1</sup>, Q.-J. Chen<sup>2</sup>, B. Hua<sup>3</sup>, J.-J. Li<sup>4</sup>, F. Ma<sup>5</sup>, Y.-S. Wang<sup>6</sup>, H. Xu<sup>1</sup>, C. Liu<sup>7</sup>, Q. Yang<sup>7</sup>, A.-X. Ma<sup>1</sup>, <sup>1</sup>China Pharmaceutical University - Jiangning Campus, Nanjing, CN,

<sup>2</sup>Guangdong Traditional Chinese Medical Hospital, Guangzhou, CN, <sup>3</sup>Beijing Hospital, Beijing, CN, <sup>4</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>5</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>6</sup>Shandong Cancer Hospital, Jinan, CN, <sup>7</sup>Shanghai Roche Pharmaceuticals Ltd, Shanghai, CN

- 09:00 - 09:00 **60P - Real-Life Use of Oncotype DX Breast Recurrence Score® Test for the Management of Patients with Node-Negative and Node-Positive Breast Cancer in the Autonomous Community of Galicia (Spain).**
- I. Fernandez-Perez<sup>1</sup>, S. Antolin Novoa<sup>2</sup>, L. De Paz Arias<sup>3</sup>, L. Vazquez Tuñas<sup>4</sup>, M.E. Perez Lopez<sup>2</sup>, S. Varela Ferreiro<sup>5</sup>, A. Gonzalez Quintas<sup>6</sup>, C. Senin Estor<sup>7</sup>, J. Cueva Banuelos<sup>8</sup>, C. Hagen<sup>9</sup>, L. Inglada-Pérez<sup>10</sup>, D. Pereiro<sup>11</sup>, L. Calvo-Martinez<sup>2</sup>, I. Carou<sup>4</sup>, L. Iglesias Rey<sup>12</sup>, A. Saenz De Miera<sup>7</sup>, T. García-Caballero<sup>13</sup>, <sup>1</sup>Hospital Alvaro Cunqueiro, Vigo, ES, <sup>2</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>3</sup>Complejo Hospitalario of Ferrol, Madrid, ES, <sup>4</sup>Complejo Hospitalario de Pontevedra, Pontevedra, ES, <sup>5</sup>HULA - Hospital Universitario Lucus Augusti, Lugo, ES, <sup>6</sup>Fundacion Centro Oncologico de Galicia, A Coruña, ES, <sup>7</sup>Hospital Povisa, Vigo, ES, <sup>8</sup>CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>9</sup>Genomic Health International Sarl, Geneva, CH, <sup>10</sup>Universidad Complutense de Madrid, Madrid, ES, <sup>11</sup>CHUVI - Complejo Hospitalario Universitario de Vigo, Vigo, ES, <sup>12</sup>Complejo Hospitalario Universitario de Ourense, Ourense, ES, <sup>13</sup>Universidade de Santiago de Compostela, Santiago de Compostela, ES
- 09:00 - 09:00 **61P - Estimating the cost of adjuvant chemotherapy in ER+/HER2- early breast cancer and distant recurrence of breast cancer in the UK**
- V. Berdunov<sup>1</sup>, S. Millen<sup>2</sup>, A. Paramore<sup>2</sup>, S. Reynia<sup>2</sup>, N. Fryer<sup>2</sup>, J. Griffin<sup>3</sup>, N. Georges<sup>2</sup>, <sup>1</sup>PHMR Ltd, London, GB, <sup>2</sup>Exact Sciences, London, GB, <sup>3</sup>Jane Griffin Associates, East Molesey, GB
- 09:00 - 09:00 **62P - Influence of PAM50 on therapeutic decisions in patients with early-stage Luminal Breast Cancer in a single centre**
- A. Olivares Hernandez<sup>1</sup>, R. Escala Cornejo<sup>2</sup>, M. García Muñoz<sup>3</sup>, L. Figuro-Perez<sup>3</sup>, J. Martín Vallejo<sup>4</sup>, M. Sancho De Salas<sup>3</sup>, M.A. Gómez Muñoz<sup>3</sup>, E. Escalera Martín<sup>3</sup>, J. Claros Ampuero<sup>3</sup>, Á. López Gutiérrez<sup>3</sup>, E. Terán Brage<sup>3</sup>, B. Barrios Collado<sup>1</sup>, D. Casado Elia<sup>5</sup>, G. Martín García<sup>3</sup>, R. Seijas Tamayo<sup>3</sup>, J.J. Cruz Hernandez<sup>1</sup>, C.A. Rodríguez<sup>6</sup>, <sup>1</sup>IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, <sup>2</sup>Complejo Asistencial de Avila - Hospital Nuestra Señora de Sonsoles Urgencias, Ávila, ES, <sup>3</sup>University Hospital of Salamanca, Salamanca, ES, <sup>4</sup>University of Salamanca, Salamanca, ES, <sup>5</sup>Hospital Universitario de Salamanca, Salamanca, ES, <sup>6</sup>Hospital Universitario de Salamanca-IBSAL. GEICAM, Spanish Breast Cancer Group, Salamanca, ES
- 09:00 - 09:00 **Early Breast cancer: Neoadjuvant therapy**
- 09:00 - 09:00 **64P - Mammographic density to predict response to neoadjuvant chemotherapy for breast cancer.**
- S. Di Cosimo<sup>1</sup>, C. Depretto<sup>2</sup>, R. Miceli<sup>2</sup>, P. Baili<sup>2</sup>, M. Sant<sup>2</sup>, G. Pruneri<sup>3</sup>, A. Vingiani<sup>4</sup>, S. Folli<sup>2</sup>, M. Bini<sup>2</sup>, M. De Santis<sup>2</sup>, G. Scaperrotta<sup>2</sup>, <sup>1</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori,

MILANO, IT, <sup>3</sup>IRCCS Fondazione Istituto Nazionale dei Tumori and University of Milan, MILANO, IT, <sup>4</sup>Fondazione IRCCS Istituto Nazionale dei Tumori Department of Pathology, IRCCS Fondazione Istituto Nazionale Tumori and University of Milan, MILANO, IT

- 09:00 - 09:00 **65P - Patient's follow-up of NEOVATTL study**  
B. Vieites<sup>1</sup>, M. López-García<sup>1</sup>, M. Martín-Salvago<sup>2</sup>, C. Ramírez-Tortosa<sup>2</sup>, R. Rezola<sup>3</sup>, M. Sancho De Salas<sup>4</sup>, L. López Vilaró<sup>5</sup>, F. Vilardell Villellas<sup>6</sup>, O. Burgués<sup>7</sup>, B. Fernández-Rodríguez<sup>8</sup>, L. Alfaro Galán<sup>1</sup>, V. Peg<sup>9</sup>, <sup>1</sup>IBIS - Instituto de Biomedicina de Sevilla - Campus Hospital Universitario Virgen del Rocío, Seville, ES, <sup>2</sup>Hospital Universitario Materno-Infantil, Jaén, ES, <sup>3</sup>Onkologikoa Kutxa Fundazioa, Donostia, ES, <sup>4</sup>University Hospital of Salamanca, Salamanca, ES, <sup>5</sup>Hospital de La Santa Creu I Sant, Barcelona, ES, <sup>6</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>7</sup>Hospital Clínico Universitario de, Valencia, ES, <sup>8</sup>Complejo Hospitalario,, Santiago de Compostela, ES, <sup>9</sup>Hospital Universitari Vall, Barcelona, ES
- 09:00 - 09:00 **66P - Baseline menopausal status, Ki-67 and stromal tumor-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): exploratory analysis in GeparSixto**  
S.I. Labidi-Galy<sup>1</sup>, A. Schneeweiss<sup>2</sup>, H.P. Sinn<sup>3</sup>, J.-U. Blohmer<sup>4</sup>, L. Romanens<sup>5</sup>, D.-M. Zahm<sup>6</sup>, J. Huober<sup>7</sup>, D. Dohnal<sup>8</sup>, T. Link<sup>9</sup>, C. Hanusch<sup>10</sup>, C. Jackisch<sup>11</sup>, P.A. Fasching<sup>12</sup>, C. Solbach<sup>13</sup>, K. Rhiem<sup>14</sup>, C. Denkert<sup>15</sup>, K. Weber<sup>16</sup>, B. Lederer<sup>17</sup>, M. Untch<sup>18</sup>, S. Loibl<sup>19</sup>, J. Furlanetto<sup>17</sup>, <sup>1</sup>Université de Genève (UNIGE) - Centre Médical Universitaire (CMU), Geneva, CH, <sup>2</sup>Nationales Centrum für Tumorerkrankungen, Heidelberg, DE, <sup>3</sup>University Hospital Heidelberg, Heidelberg, DE, <sup>4</sup>St. Gertrauden-Krankenhaus, Berlin, DE, <sup>5</sup>University of Geneva - Fondation Pour Recherches Medicales, Geneva, CH, <sup>6</sup>SRH Wald-Klinikum Gera, Gera, DE, <sup>7</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>8</sup>Dre. Dohnal and Partner, Düsseldorf, DE, <sup>9</sup>Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, <sup>10</sup>Rotkreuzklinikum, München, DE, <sup>11</sup>Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>12</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>13</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>14</sup>University Hospital Cologne, Köln, DE, <sup>15</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>16</sup>GBG, Neu-Isenburg, DE, <sup>17</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>18</sup>Helios Klinikum Berlin Buch, Berlin, DE, <sup>19</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE
- 09:00 - 09:00 **67P - The Role of FDG PET/CT to Omit Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer**  
E. Tanrikulu Simsek<sup>1</sup>, E. Çoban<sup>2</sup>, E. Atag<sup>2</sup>, M. Sari<sup>2</sup>, S. Gungor<sup>3</sup>, M.A. Ozturk<sup>4</sup>, F. Aker<sup>2</sup>, G. Gurleyik<sup>2</sup>, <sup>1</sup>Marmara University Hospital, Istanbul, TR, <sup>2</sup>Haydarpasa Numune Training and Research Hospital, Istanbul, TR, <sup>3</sup>Istanbul Medeniyet University, Istanbul, TR, <sup>4</sup>Bahcesehir University, Istanbul, TR
- 09:00 - 09:00 **68P - A meta-analysis of the efficacy of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer**  
Y. Li<sup>1</sup>, L. Xing<sup>2</sup>, X. Yin<sup>2</sup>, H. Li<sup>2</sup>, G. Ren<sup>2</sup>, <sup>1</sup>1st Affiliated Hospital of Chongqing Medical University, Chongqing, CN, <sup>2</sup>The first Affiliated Hospital of Chongqing Medical University, Chongqing, CN

- 09:00 - 09:00 **69P - Real world impact of the introduction of Targeted Axillary Dissection (TAD) following Neo-adjuvant Chemotherapy (NAC)**  
G. Mohammadi-Zaniani<sup>1</sup>, R. Mclean<sup>2</sup>, A. Pieri<sup>2</sup>, M. Verrill<sup>3</sup>, N. Cresti<sup>3</sup>, H. Cain<sup>2</sup>, <sup>1</sup>NUTH - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, GB, <sup>2</sup>Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, GB, <sup>3</sup>Northern Centre For Cancer Care, Newcastle Upon Tyne, GB
- 09:00 - 09:00 **70P - Neoadjuvant chemotherapy in breast cancer in the last 2 decades: are we improving survival? Retrospective analysis in a single institution**  
J. Ponce<sup>1</sup>, G. Peiro<sup>1</sup>, Y. Montoyo<sup>2</sup>, S. Delgado<sup>1</sup>, H. Ballester<sup>1</sup>, T. Martín<sup>1</sup>, A. Ramos<sup>1</sup>, F. Aranda<sup>1</sup>, M. Niveiro<sup>1</sup>, M. Reche<sup>1</sup>, J. Ballesteros<sup>1</sup>, M. Moya<sup>1</sup>, I. Lozano<sup>1</sup>, L. Gomez<sup>1</sup>, D. Parra<sup>1</sup>, B. Massuti<sup>1</sup>, <sup>1</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>2</sup>Hospital General Universitario de Alicante, ISABIAL, Alicante, ES
- 09:00 - 09:00 **71P - Impact of body mass index (BMI) on pathological complete response (pCR) and survival of breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC)**  
D. Aguiar Bujanda<sup>1</sup>, L. Ros Sanjuan<sup>2</sup>, D. Perez Cabrera<sup>2</sup>, L. Croissier Sanchez<sup>2</sup>, M. Mori De Santiago<sup>2</sup>, M. Hernandez Sosa<sup>2</sup>, A. Vargas Prado<sup>2</sup>, S. Galvan Ruiz<sup>2</sup>, C. Antonilli Perez<sup>2</sup>, R. Ten Benajes<sup>2</sup>, B. Fox<sup>2</sup>, R. Martinez Garcia-Cervantes<sup>2</sup>, G. Rubio Romero<sup>2</sup>, R. Hanselmann<sup>2</sup>, S. Saura Grau<sup>2</sup>, <sup>1</sup>Hospital de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, ES, <sup>2</sup>Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, ES
- 09:00 - 09:00 **72TiP - ROSALINE: a phase II, single-arm, neoadjuvant study of targeting ROS1 in combination with endocrine therapy (ET) in invAsive Lobular carcinoma of the brEast**  
E. Agostinetto<sup>1</sup>, M. Paesmans<sup>2</sup>, L. Ameye<sup>2</sup>, I. Veys<sup>2</sup>, L. Buisseret<sup>2</sup>, P. Neven<sup>3</sup>, D. Taylor<sup>4</sup>, C. Fontaine<sup>5</sup>, F.P. Duhoux<sup>6</sup>, J.-L. Canon<sup>7</sup>, H. Denys<sup>8</sup>, F. Coussy<sup>9</sup>, C. Chakiba<sup>10</sup>, B. Pistilli<sup>11</sup>, M. Piccart<sup>12</sup>, M. Ignatiadis<sup>12</sup>, P. Aftimos<sup>12</sup>, <sup>1</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>2</sup>Institut Jules Bordet, Brussels, BE, <sup>3</sup>Universitaire Ziekenhuizen Leuven, Leuven, BE, <sup>4</sup>CHU UCL Namur Sainte-Elisabeth, Namur, BE, <sup>5</sup>UZ Brussel, Brussels, BE, <sup>6</sup>Cliniques universitaires Saint-Luc, Brussels, BE, <sup>7</sup>Grand Hôpital de Charleroi, Charleroi, BE, <sup>8</sup>UZ Gent, Gent, BE, <sup>9</sup>Institut Curie, Paris Cedex, FR, <sup>10</sup>Institut Bergonié, Bordeaux, FR, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>Institute Jules Bordet, Brussels, BE
- 09:00 - 09:00 **73TiP - SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in Hormone Receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)**  
E. Ciruelos<sup>1</sup>, F.J. Salvador Bofill<sup>2</sup>, A. Perello Martorell<sup>3</sup>, E. Alba Conejo<sup>4</sup>, X. González-Farré<sup>5</sup>, P. Palacios-Ozores<sup>6</sup>, M. Merino<sup>7</sup>, P. Villagrasa<sup>8</sup>, E. Vila Navarro<sup>9</sup>, T. Pascual<sup>10</sup>, A. Prat<sup>10</sup>, S. Pernas Simon<sup>11</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital Universitario Virgen Valme, Seville, ES, <sup>3</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>4</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>5</sup>Hospital General de Catalunya, Sant Cugat del Vallés, ES, <sup>6</sup>CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>7</sup>Hospital Infanta Sofia, Madrid, ES, <sup>8</sup>SOLTI Breast Cancer Research Group, Barcelona,

ES, <sup>9</sup>SOLTI Grupo Espanol de Estudio, Barcelona, ES, <sup>10</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>11</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

- 09:00 - 09:00 **Early Breast cancer: Surgery and radiotherapy**
- 09:00 - 09:00 **74P - Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening**  
K. Czene<sup>1</sup>, M. Eriksson<sup>2</sup>, P. Hall<sup>3</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Karolinska Institutet, Huddinge, SE, <sup>3</sup>Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE
- 09:00 - 09:00 **75P - Use of Low-dose Tamoxifen to Improve Mammographic Screening Sensitivity in Premenopausal Women**  
M. Eriksson<sup>1</sup>, E. Conant<sup>2</sup>, K. Czene<sup>3</sup>, P. Hall<sup>4</sup>, <sup>1</sup>Karolinska Institutet, Huddinge, SE, <sup>2</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, US, <sup>3</sup>Karolinska Institutet, Stockholm, SE, <sup>4</sup>Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE
- 09:00 - 09:00 **76P - The Clinical survival benefit of postmastectomy radiotherapy patients screened form T1-2N1M0 breast cancer according to tumor size and the number of lymph nodes**  
H. Yang<sup>1</sup>, M. Chen<sup>1</sup>, L. Hou<sup>2</sup>, Y. Huang<sup>1</sup>, <sup>1</sup>Affiliated Suining Central Hospital of Chongqing Medical University, Suining, CN, <sup>2</sup>Affiliated Hospital of North Sichuan Medical College, Nanchong, CN
- 09:00 - 09:00 **77P - the cost effectiveness and cosmetic outcome of vacuum assisted excision compared to surgical excision for the treatment of benign and high-risk lesions**  
E. Van De Voort<sup>1</sup>, G.M. Struik<sup>2</sup>, C. Verhoef<sup>3</sup>, T. Klem<sup>4</sup>, <sup>1</sup>SFVG - St Franciscus Gasthuis, Rotterdam, NL, <sup>2</sup>Reinier de Graaf Gasthuis, Delft, NL, <sup>3</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>4</sup>Franciscus Gasthuis en Vlietland, Rotterdam, NL
- 09:00 - 09:00 **78P - A dosimetric study of the non-intended irradiation to the internal mammary lymph nodes during locoregional radiotherapy to the breast**  
H. Yassen<sup>1</sup>, A. Ismail<sup>2</sup>, A.M. Amin Darwish<sup>3</sup>, A. Munir<sup>4</sup>, M.I. Abouegylah<sup>3</sup>, A. Kandil<sup>1</sup>, <sup>1</sup>Alexandria Faculty of Medicine, Alexandria, EG, <sup>2</sup>Specialized Universal Network of Oncology (SUN), Alexandria, EG, <sup>3</sup>University of Alexandria - Faculty of Medicine, Alexandria, EG, <sup>4</sup>Alexandria University, Alexandria, EG
- 09:00 - 09:00 **79P - Targeted Intraoperative Radiotherapy vs External Beam Radiotherapy in Early-Stage Breast Cancer Patients: A Systematic Review and Meta-Analysis**  
A. Hadisurya<sup>1</sup>, C. Chrystelle<sup>1</sup>, F. Tandy<sup>1</sup>, M. Suciningtias<sup>1</sup>, R. Heriyanto<sup>1</sup>, A. Kurniawan<sup>1</sup>, A. Giselsania<sup>2</sup>, <sup>1</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, <sup>2</sup>University of Indonesia - Faculty of Medicine, Jakarta, ID
- 09:00 - 09:00 **80P - Radiolabelled Trastuzumab Fab as a theranostic molecule for HER2**

**positive breast cancers**

Y. Rathore<sup>1</sup>, J. Shukla<sup>1</sup>, B. Mittal<sup>2</sup>, G. Singh<sup>1</sup>, K. Gopal<sup>3</sup>, R. Kumar<sup>1</sup>, A. Bal<sup>1</sup>, I. Laroia<sup>1</sup>, T. Lakhanpal<sup>1</sup>, <sup>1</sup>PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN, <sup>2</sup>Banaras Hindu University, Varanasi, IN, <sup>3</sup>CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, IN

09:00 - 09:00 **81P - Is there a benefit for nodal evaluation as part of the post-lumpectomy imaging study before Radiotherapy?**

A. Pires<sup>1</sup>, A. Laranja<sup>2</sup>, F. Sousa<sup>1</sup>, B. De Castro<sup>1</sup>, S. Sarandão<sup>1</sup>, S. Costa<sup>1</sup>, F. Fernandes<sup>1</sup>, H. Pereira<sup>1</sup>, <sup>1</sup>Instituto Portugues de Oncologia - Porto, Porto, PT, <sup>2</sup>Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E, Porto, PT

09:00 - 09:00 **82P - Predicting invasive disease and lymph node involvement in patients with preoperative diagnosis of ductal carcinoma in situ**

A. Tondare<sup>1</sup>, F. Irakleidis<sup>2</sup>, J. Timbres<sup>3</sup>, H. Hamed<sup>2</sup>, A. Kothari<sup>2</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>3</sup>King's College, London, GB

09:00 - 09:00 **83P - Axillary Reverse Mapping Using Near-infrared fluorescence Imaging in Invasive Breast Cancer (ARMONIC Study)**

A. Conversano<sup>1</sup>, M. Abbaci<sup>2</sup>, M. Karim<sup>2</sup>, M.C. Mathieu<sup>2</sup>, F. De Leeuw<sup>2</sup>, S. Michiels<sup>3</sup>, C. Laplace-Builhé<sup>2</sup>, C. Mazouni<sup>4</sup>, <sup>1</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Gustave Roussy -, Villejuif, FR, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Institut Gustave Roussy, Villejuif, FR

09:00 - 09:00 **84P - Prospective Comparative Study of Dosimetric Parameters and Acute Radiation Toxicity of 3-Dimensional Conformal Radiotherapy (3DCRT) And Volumetric Modulated Arc Therapy (VMAT) In Post Mastectomy Carcinoma Breast Patients**

P. Inampudi<sup>1</sup>, R. Seam<sup>1</sup>, L. Pandey<sup>2</sup>, D. Malik<sup>1</sup>, A. Pandey<sup>1</sup>, A. Anjali<sup>1</sup>, A. Hakim<sup>3</sup>, R. Mahajan<sup>3</sup>, S. Sharma<sup>1</sup>, <sup>1</sup>Maharshi Markandeshwar Institute of Medical Sciences and Research, Ambala, IN, <sup>2</sup>All India Institute of Medical Sciences, Rishikesh, IN, <sup>3</sup>PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN

09:00 - 09:00 **85P - Hypofractionated Radiotherapy for Breast Cancer: Does obesity increase the skin toxicity?**

R. Ben Amor<sup>1</sup>, M. Bohli<sup>2</sup>, D. Aissaoui<sup>3</sup>, J. Yahiaoui<sup>3</sup>, A. Hamdoun<sup>3</sup>, L. Kochbati<sup>2</sup>, <sup>1</sup>Institut Salah Azaiz, Tunis, TN, <sup>2</sup>Hopital Abderrahmen Mami de Pneumo-Phistiologie, Ariana, TN, <sup>3</sup>Abderrahman Mami Hospital, Ariana, TN

09:00 - 09:00 **86P - The impact of the introduction of vacuum assisted excision on clinical management and outcomes of benign and high-risk lesions**

E. Van De Voort<sup>1</sup>, G.M. Struik<sup>2</sup>, E. Birnie<sup>3</sup>, R. Sinke<sup>3</sup>, M. Macco<sup>3</sup>, K. Verhoef<sup>4</sup>, T. Klem<sup>3</sup>, <sup>1</sup>SFVG - St Franciscus Gasthuis, Rotterdam, NL, <sup>2</sup>Reinier de Graaf Gasthuis, Delft, NL, <sup>3</sup>Franciscus Gasthuis en Vlietland, Rotterdam, NL, <sup>4</sup>Erasmus MC - University Medical Center, Rotterdam, NL

09:00 - 09:00 **Immunotherapy**

- 09:00 - 09:00 **87P - Epigenetics of the epigenetics: impact of Let-7a expression restoration in CD8+ cells of HER2+ breast cancer patients**  
T. Monier<sup>1</sup>, A. Samir<sup>1</sup>, A. El Khodiry<sup>1</sup>, R. Abdel Tawab<sup>2</sup>, H. El Tayebi<sup>1</sup>, <sup>1</sup>GUC - German University in Cairo, New Cairo, EG, <sup>2</sup>Ain Shams University, Cairo, EG
- 09:00 - 09:00 **88P - CXCR2 Small Molecule Antagonists: a Novel Approach to Enhance the Effect of PDL-1 Inhibitors in Triple Negative Breast Cancer**  
A. Ghallab<sup>1</sup>, R. Abdel Tawab<sup>2</sup>, H. El Tayebi<sup>1</sup>, <sup>1</sup>GUC - German University in Cairo, New Cairo, EG, <sup>2</sup>Ain Shams University, Cairo, EG
- 09:00 - 09:00 **89P - High expression of miR-18a drives immunosuppressive activity in ER-positive breast cancer**  
M. Nair<sup>1</sup>, S. Vp<sup>1</sup>, J. Prabhu<sup>2</sup>, T. Sridhar<sup>2</sup>, <sup>1</sup>St. John's Research Institute, Bangalore, IN, <sup>2</sup>St Johns Research Institute, Bangalore, IN
- 09:00 - 09:00 **90TiP - Monalizumab and trastuzumab in metastatic HER2-positive breast cancer: MIMOSA-trial**  
V. Geurts<sup>1</sup>, L. Voorwerk<sup>2</sup>, K. Sikorska<sup>1</sup>, M. Van Dongen<sup>3</sup>, I. Kemper<sup>1</sup>, I. Mandjes<sup>1</sup>, J. Haanen<sup>4</sup>, G. Sonke<sup>1</sup>, M. Kok<sup>2</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>Leiden University Medical Center (LUMC), Leiden, NL, <sup>4</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL
- 09:00 - 09:00 **Metastatic Breast cancer**
- 09:00 - 09:00 **97P - Is continuing CDK4-6 inhibitor therapy safe during the COVID-19 pandemic? A UK Cancer Centre Experience**  
V. Angelis<sup>1</sup>, P. Mcfarlane<sup>1</sup>, N. Cunningham<sup>1</sup>, S. Gennatas<sup>1</sup>, S. Johnston<sup>2</sup>, A. Okines<sup>3</sup>, S. Mcgrath<sup>1</sup>, <sup>1</sup>The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, <sup>2</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>3</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 09:00 - 09:00 **98P - Final results from AVANTI, a multicentre German observational study of 1st-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC)**  
V. Mueller<sup>1</sup>, M. Ruhnke<sup>2</sup>, O. Hoffmann<sup>3</sup>, A. Grafe<sup>4</sup>, O. Tomé<sup>5</sup>, W. Fett<sup>6</sup>, H.-R. Bruch<sup>7</sup>, A.-K. Sommer<sup>8</sup>, A. Schneeweiss<sup>9</sup>, <sup>1</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup>Paracelsus-Klinik Osnabrück, and <sup>3</sup>Helios Klinikum Aue, Aue, DE, <sup>3</sup>Universitaetsklinikum Essen, Essen, DE, <sup>4</sup>MVZ Nordhausen gGmbH, Praxis Dr Grafe/Brustzentrum der Frauenklinik, Südharz-Klinikum Nordhausen gGmbH, Nordhausen, DE, <sup>5</sup>St. Vincentius-Kliniken gAG, Karlsruhe, DE, <sup>6</sup>MVZ West GmbH, Wuppertal, DE, <sup>7</sup>Facharzt fuer Innere Medizin Haematologie und Onkologie, Berlin, DE, <sup>8</sup>Roche Pharma AG, Grenzach-Wyhlen, DE, <sup>9</sup>Nationales Centrum für Tumorerkrankungen, Heidelberg, DE

- 09:00 - 09:00 **99P - Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome**
- B. Kingston<sup>1</sup>, R. Cutts<sup>2</sup>, M. Beaney<sup>1</sup>, G. Walsh-Crestani<sup>1</sup>, S. Hrebien<sup>3</sup>, L. Kilburn<sup>2</sup>, S. Kernaghan<sup>2</sup>, L. Moretti<sup>2</sup>, K. Wilkinson<sup>2</sup>, I. Macpherson<sup>4</sup>, R. Baird<sup>5</sup>, R. Roylance<sup>6</sup>, J. Reis-Filho<sup>7</sup>, M. Hubank<sup>8</sup>, I. Faull<sup>9</sup>, K. Banks<sup>10</sup>, I. Garcia-Murillas<sup>1</sup>, J. Bliss<sup>2</sup>, A. Ring<sup>8</sup>, N. Turner<sup>8</sup>, <sup>1</sup>ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, <sup>2</sup>ICR - Institute of Cancer Research, London, GB, <sup>3</sup>The Institute of Cancer Research, London, London, GB, <sup>4</sup>BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, <sup>5</sup>Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, <sup>6</sup>UCLH - University College London Hospitals NHS Foundation Trust, London, GB, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Guardant Health, Inc., Redwood City, US
- 09:00 - 09:00 **100P - Efficacy of Enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a Phase 2 clinical study**
- C. Palmieri<sup>1</sup>, H. Linden<sup>2</sup>, S. Birrell<sup>3</sup>, E. Lim<sup>4</sup>, L. Schwartzberg<sup>5</sup>, H. Rugo<sup>6</sup>, P. Cobb<sup>7</sup>, K. Jain<sup>8</sup>, C. Vogel<sup>9</sup>, J. O'Shaughnessy<sup>10</sup>, S. Johnston<sup>11</sup>, R. Getzenberg<sup>12</sup>, K.G. Barnette<sup>12</sup>, M. Steiner<sup>12</sup>, A. Brufsky<sup>13</sup>, B. Overmoyer<sup>14</sup>, <sup>1</sup>NHS Liverpool Clinical Laboratories - Royal Liverpool University Hospital NHS Trust, Liverpool, GB, <sup>2</sup>University of Washington Seattle Cancer Care Alliance, Seattle, US, <sup>3</sup>Wellend Health/Burside Hospital, Toorak Gardens, AU, <sup>4</sup>St Vincent's Hospital and Garvan Institute of Medical Research, Sydney, AU, <sup>5</sup>West Cancer Center, Germantown, US, <sup>6</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>7</sup>Cancer Centers of Montana, Billings, US, <sup>8</sup>Ashland Bellefonte Cancer Center, Ashland, US, <sup>9</sup>University of Miami, Miami, US, <sup>10</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>11</sup>Royal Marsden Hospital NHS Foundation Trust, London, GB, <sup>12</sup>Veru Inc, Miami, US, <sup>13</sup>Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>14</sup>Dana Farber Cancer Institute, Boston, US
- 09:00 - 09:00 **101P - E-cadherin inactivation by Trop-2 drives EMT-less metastatic relapse in triple-negative breast cancer**
- S. Alberti<sup>1</sup>, E. Guerra<sup>2</sup>, R. Lattanzio<sup>2</sup>, M. Ceci<sup>2</sup>, K. Boujnah<sup>1</sup>, V. Relli<sup>2</sup>, V. Garbo<sup>1</sup>, A. Moschella<sup>1</sup>, D. Altomare<sup>3</sup>, R. Depalo<sup>3</sup>, M. Trerotola<sup>2</sup>, <sup>1</sup>AOU Policlinico G. Martino - Università di Messina, Messina, IT, <sup>2</sup>University of Chieti, Chieti Scalo, IT, <sup>3</sup>University of Bari, Bari, IT
- 09:00 - 09:00 **102P - Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases: characteristics and validation of prognostic models in a large real-life database**
- M. Carausu<sup>1</sup>, M. Carton<sup>2</sup>, A. Darlix<sup>3</sup>, D. Pasquier<sup>4</sup>, M. Leheurteur<sup>5</sup>, M. Debled<sup>6</sup>, M.-A. Mouret-Reynier<sup>7</sup>, A. Gonçalves<sup>8</sup>, F. Dalenc<sup>9</sup>, B. Verret<sup>10</sup>, M. Campone<sup>11</sup>, J.-M. Ferrero<sup>12</sup>, C. Levy<sup>13</sup>, J.-D. Fumet<sup>14</sup>, C. Lefeuvre-Plesse<sup>15</sup>, T. Petit<sup>16</sup>, C. Jouannaud<sup>17</sup>, L. Larrouquere<sup>18</sup>, M. Chevrot<sup>19</sup>, L. Cabel<sup>20</sup>, <sup>1</sup>Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, <sup>2</sup>Institut Curie, Paris, FR, <sup>3</sup>ICM Regional Cancer Institute of Montpellier, Montpellier, FR, <sup>4</sup>Centre Oscar Lambret, Lille, FR, <sup>5</sup>Centre Henri Becquerel, Rouen, FR, <sup>6</sup>Institut Bergonié, Bordeaux, FR, <sup>7</sup>Centre Jean-Perrin, Clermont Ferrand, FR, <sup>8</sup>Institute

Paoli Calmettes, Marseille, FR, <sup>9</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>10</sup>Institut Gustave Roussy, Villejuif, FR, <sup>11</sup>Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, SAINT-HERBLAIN, FR, <sup>12</sup>Centre Antoine Lacassagne, Nice, FR, <sup>13</sup>Centre Francois Baclesse, Caen, FR, <sup>14</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>15</sup>Centre Eugene - Marquis, Rennes, FR, <sup>16</sup>Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, <sup>17</sup>Institut de Cancérologie Jean-Godinot, Reims, FR, <sup>18</sup>CHU Grenoble Alpes - Site Nord La Tronche, La Tronche, FR, <sup>19</sup>Unicancer, Paris, FR, <sup>20</sup>Hôpital René Huguenin - Institut Curie, Saint-Cloud, FR

- 09:00 - 09:00 **103P - Long-term results and bone-protective effect of everolimus added to letrozole and ovarian function suppression for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: an updated analysis of the LEO study**
- H. Jeong<sup>1</sup>, J.H. Jeong<sup>2</sup>, J.E. Kim<sup>2</sup>, J.-H. Ahn<sup>2</sup>, K.H. Jung<sup>2</sup>, S.-J. Koh<sup>3</sup>, J. Cheon<sup>3</sup>, J.H. Sohn<sup>4</sup>, G.M. Kim<sup>4</sup>, K.S. Lee<sup>5</sup>, S.H. Sim<sup>5</sup>, I.H. Park<sup>6</sup>, S.-B. Kim<sup>1</sup>, <sup>1</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center, Seoul, KR, <sup>3</sup>Ulsan University Hospital, Ulsan, KR, <sup>4</sup>Severance Hospital, Seoul, KR, <sup>5</sup>National Cancer Center, Goyang, KR, <sup>6</sup>Korea University Guro Hospital, Seoul, KR
- 09:00 - 09:00 **104P - Clinical characteristics of patients (pts) with complete response (CR) to abemaciclib-based endocrine therapy (ET) in MONARCH 2 (M2) and MONARCH 3 (M3)**
- J. Huober<sup>1</sup>, E.-M. Grischke<sup>2</sup>, S. Guiu<sup>3</sup>, N. Quenel Tueux<sup>4</sup>, N. Chouaki<sup>5</sup>, C. Stoffregen<sup>6</sup>, A. Korfel<sup>6</sup>, F. Lerebours<sup>7</sup>, <sup>1</sup>Universitaetsfrauenklinik Ulm, Ulm, DE, <sup>2</sup>Universitätsklinikum Tübingen, Tuebingen, DE, <sup>3</sup>ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, <sup>4</sup>Institute Bergonié, Bordeaux, FR, <sup>5</sup>Eli Lilly and Company, Leicestershire, GB, <sup>6</sup>Lilly Deutschland GmbH, Bad Homburg vor der Hoehe, DE, <sup>7</sup>Hôpital René Huguenin - Institut Curie, St. Cloud, FR
- 09:00 - 09:00 **105P - A comparative study of Cisplatin plus Adriamycin compared with Cyclophosphamide plus Adriamycin in patients with untreated metastatic triple negative Breast Cancer (TNBC)**
- S. Yaqub<sup>1</sup>, M. Khokhar<sup>1</sup>, A. Zafar<sup>2</sup>, A.W. Goraya<sup>3</sup>, Z.A.K. Niazi<sup>2</sup>, S. Ishaq<sup>1</sup>, <sup>1</sup>King Edward Medical University, Lahore, PK, <sup>2</sup>Hameed Latif Hospital, Lahore, PK, <sup>3</sup>Mayo Hospital, Lahore, PK
- 09:00 - 09:00 **106P - Palbociclib (PAL) in Male Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer (ABC): Pt Characteristics and Treatment (Tx) Patterns From the POLARIS Study**
- J. Blum<sup>1</sup>, C. Dicristo<sup>2</sup>, D. Gordon<sup>3</sup>, M. Karuturi<sup>4</sup>, D. Oubre<sup>5</sup>, E. Jepsen<sup>6</sup>, J. Cuevas<sup>7</sup>, S. Lakhanpal<sup>8</sup>, Z. Zhang<sup>9</sup>, M. Drucker<sup>10</sup>, Y. Wang<sup>11</sup>, D. Tripathy<sup>12</sup>, <sup>1</sup>Texas Oncology, Baylor-Sammons Cancer Center, Dallas, US, <sup>2</sup>Pfizer, Cambridge, US, <sup>3</sup>Munson Medical Center, Traverse City, US, <sup>4</sup>The M. D. Anderson Cancer Center, Houston, US, <sup>5</sup>Ponchartrain Cancer Center, Hammond, US, <sup>6</sup>Novant Health, Winston-Salem, US, <sup>7</sup>St. Louis Cancer Care, St. Louis, US, <sup>8</sup>St Vincent's Birmingham, Birmingham, US, <sup>9</sup>No place of work provided, No City Provided, NA, <sup>10</sup>Icon plc, San Francisco, US, <sup>11</sup>Pfizer Inc - USA, New York, US, <sup>12</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US

- 09:00 - 09:00 **107P - CDK4/6i adjustment & tumour response in the COVID-19 era**  
Z. Tippu<sup>1</sup>, C. Ryan<sup>2</sup>, C. Harper-Wynne<sup>2</sup>, <sup>1</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>2</sup>Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB
- 09:00 - 09:00 **108P - Epigenetic regulation of the putative breast cancer metastasis suppressor gene SCN4B**  
L. Hilgers<sup>1</sup>, A. Hartmann<sup>2</sup>, P.A. Fasching<sup>2</sup>, S. Villwock<sup>1</sup>, L. Moll<sup>1</sup>, S. Roger<sup>3</sup>, R. Knüchel-Clarke<sup>1</sup>, F. Steib<sup>1</sup>, E. Dahl<sup>1</sup>, <sup>1</sup>Uniklinik RWTH Aachen, Aachen, DE, <sup>2</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>3</sup>Université de Tours, Tours, FR
- 09:00 - 09:00 **109P - Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)**  
J.C. Laguna<sup>1</sup>, F. Brasó-Maristany<sup>2</sup>, T. Pascual<sup>1</sup>, A. Rodriguez Hernandez<sup>1</sup>, N. Chic<sup>2</sup>, F. Schettini<sup>3</sup>, E. Sanfeliu Torres<sup>4</sup>, B. Gonzalez-Farre<sup>4</sup>, D. Martínez<sup>2</sup>, P. Galván<sup>2</sup>, V. Díez-Guardia<sup>2</sup>, B. Adamo<sup>1</sup>, M. Vidal<sup>4</sup>, M.C. Guillen Sacoto<sup>5</sup>, R. Moreno<sup>4</sup>, A. Prat<sup>1</sup>, M. Muñoz<sup>4</sup>, O. Martínez-Sáez<sup>4</sup>, <sup>1</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>2</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>3</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>4</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>5</sup>IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES
- 09:00 - 09:00 **110P - Adenoid cystic carcinoma of the breast: a case series of 17 patients and literature review**  
B. Mery<sup>1</sup>, S. Witmeyer<sup>2</sup>, O. Tredan<sup>1</sup>, T. Bachelot<sup>1</sup>, <sup>1</sup>Centre Léon Bérard, Lyon, FR, <sup>2</sup>Universite Claude Bernard Lyon 1 - Campus Rockefeller, Lyon, FR
- 09:00 - 09:00 **111P - Real-world outcomes of patients with breast cancer liver metastases treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study**  
D. Arnold<sup>1</sup>, T. Balli<sup>2</sup>, R. Cianni<sup>3</sup>, B. Peynircioglu<sup>4</sup>, T. Pfammatter<sup>5</sup>, N. De Jong<sup>6</sup>, T. Helmberger<sup>7</sup>, <sup>1</sup>Asklepios Klinik Altona - Asklepios Kliniken, Hamburg, DE, <sup>2</sup>Cukurova University, Adana, TR, <sup>3</sup>Ospedale Santa Maria Goretti, Latina, IT, <sup>4</sup>Hacettepe University, Ankara, TR, <sup>5</sup>Universitätsspital Zürich, Zürich, CH, <sup>6</sup>CIRSE - Cardiovascular and Interventional Radiological Society of Europe, Vienna, AT, <sup>7</sup>Klinikum Neuperlach-Staedtisches Klinikum Muenchen, Munich, DE
- 09:00 - 09:00 **112P - Women with short survival after diagnosis of metastatic breast cancer - a population-based registry study**  
C. Boman<sup>1</sup>, L. Edman Kessler<sup>1</sup>, J. Bergh<sup>2</sup>, A. Matikas<sup>2</sup>, T. Foukakis<sup>1</sup>, <sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Karolinska Institutet - Bioclinicum, Solna, SE
- 09:00 - 09:00 **113P - Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: results from the Institut Curie's database.**  
C. Chalumeau<sup>1</sup>, J.-Y. Pierga<sup>1</sup>, G. Pierron<sup>1</sup>, S. Ballet<sup>1</sup>, S. Nasr<sup>1</sup>, A. Vincent-Salomon<sup>1</sup>, P. Vuagnat<sup>2</sup>, A. Bellesoeur<sup>1</sup>, M. Carton<sup>1</sup>, F.C. Bidard<sup>1</sup>, F. Lerebours<sup>3</sup>, <sup>1</sup>Institut Curie, Paris, FR, <sup>2</sup>Institut Curie, Saint cloud, FR, <sup>3</sup>Hôpital René Huguenin - Institut Curie, St. Cloud,

FR

- 09:00 - 09:00 **114P - Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer**  
K. Kristensen<sup>1</sup>, A. Jensen<sup>1</sup>, A. Kodahl<sup>2</sup>, T. Berg<sup>3</sup>, I.M. Thomsen<sup>3</sup>, <sup>1</sup>Aarhus University Hospital, Aarhus, DK, <sup>2</sup>Odense University Hospital, Odense, DK, <sup>3</sup>Copenhagen University Hospital, Copenhagen, DK
- 09:00 - 09:00 **115P - Palbociclib-Letrozole in advanced breast cancer - a real world review from a regional cancer centre in the United Kingdom.**  
S. Bose<sup>1</sup>, V. Kuriakose<sup>2</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>NEW CROSS HOSPITAL, Wolverhampton, GB
- 09:00 - 09:00 **116P - Real-world treatment patterns and clinical effectiveness of eribulin in HR+/HER2- metastatic breast cancer patients in the United States**  
S. Mougalian<sup>1</sup>, J. Zhang<sup>2</sup>, J. Kish<sup>3</sup>, M. Zettler<sup>3</sup>, B. Feinberg<sup>3</sup>, <sup>1</sup>Yale School of Medicine, New Haven, US, <sup>2</sup>Eisai Inc., Woodcliff Lake, US, <sup>3</sup>Cardinal Health Specialty Solutions, Dublin, US
- 09:00 - 09:00 **117P - Pretherapeutic neutrophil-lymphocyte ratio as prognostic and predictive factors in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.**  
P. Rottier, A. Da Silva, C. Levy, D. Allouache, A. Johnson, I. Hrab, A. Faveyrial, K. Gunzer, C. Segura Djezzer, A. Morel, M. Villemin, C. Boscher, L. Boismoreau, F. Cherifi, J. Lequesne, G. Emile, Centre Francois Baclesse, Caen, FR
- 09:00 - 09:00 **118P - Determinants of timing to metastasis in breast cancer patients in Albanian**  
F. Kraja<sup>1</sup>, A. Hoti<sup>2</sup>, I. Akshija<sup>2</sup>, A. Kristo<sup>2</sup>, E. Tola<sup>3</sup>, O. Shazi<sup>2</sup>, H. Nina<sup>2</sup>, <sup>1</sup>Tirana University Hospital Center Mother Theresa, Tirana, AL, <sup>2</sup>Tirana University Hospital Center "Mother Teresa", Tirana, AL, <sup>3</sup>Fier Regional Hospital, Fier, AL
- 09:00 - 09:00 **119P - Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence**  
J.H. Jeong<sup>1</sup>, H. Jeong<sup>2</sup>, J.E. Kim<sup>1</sup>, J.-H. Ahn<sup>1</sup>, K.H. Jung<sup>1</sup>, S.-B. Kim<sup>2</sup>, <sup>1</sup>Asan Medical Center, Seoul, KR, <sup>2</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 09:00 - 09:00 **120P - Prognostic significance of SAMHD1 expression in breast cancer**  
M. Margeli Vila<sup>1</sup>, E. Felip<sup>1</sup>, L. Gutierrez<sup>2</sup>, E. Riveira<sup>2</sup>, V. Quiroga<sup>3</sup>, M. Romeo<sup>3</sup>, B. Cirauqui<sup>3</sup>, I. Teruel<sup>3</sup>, A. Pous<sup>3</sup>, A. Ferrando<sup>3</sup>, A. Martinez-Cardús<sup>4</sup>, E. Ballana<sup>2</sup>, <sup>1</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>2</sup>IRSICAIXA, Badalona, ES, <sup>3</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol); B-ARGO (Badalona Applied Research Group), Badalona, ES, <sup>4</sup>Badalona Applied Research Group in Oncology (B-ARGO), Badalona, ES

- 09:00 - 09:00 **121P - Impact of HER2 Low (H2L) expression on prognosis in luminal locally advanced or metastatic breast cancer (BC): A retrospective study.**  
C. Saavedra Serrano<sup>1</sup>, B. Pérez Mies<sup>1</sup>, M. Gion Cortes<sup>1</sup>, A. Cortes Salgado<sup>1</sup>, M. Fernández Abad<sup>1</sup>, N. Martínez-Jañez<sup>2</sup>, M. Soriano<sup>1</sup>, E.M. Guerra<sup>1</sup>, E. Lopez Miranda<sup>1</sup>,  
<sup>1</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>2</sup>Hospital Universitario Ramón y Cajal. GEICAM Breast Cancer Group, Madrid, ES
- 09:00 - 09:00 **122P - Abemaciclib in HR+/HER2- metastatic breast cancer: a real-world experience**  
M. Bottosso<sup>1</sup>, T. Giarratano<sup>1</sup>, C. Barbieri<sup>2</sup>, A. Menichetti<sup>1</sup>, E. Cumerlato<sup>2</sup>, F. Miglietta<sup>2</sup>, E. Genovesi<sup>2</sup>, O. Amato<sup>2</sup>, M.V. Dieci<sup>1</sup>, G. Griguolo<sup>1</sup>, V. Guarneri<sup>3</sup>, <sup>1</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>University of Padova, Padova, IT, <sup>3</sup>Istituto Oncologico Veneto IRCCS, Padova, IT
- 09:00 - 09:00 **123P - Clinical and pathological characteristics of male breast cancer at the Institute for Oncology including first line treatment in hormone receptor positive tumors**  
K. Serovic<sup>1</sup>, M. Jevric<sup>2</sup>, S. Susnjar<sup>1</sup>, I. Bozovic Spasojevic<sup>1</sup>, <sup>1</sup>Institute for Oncology and Radiology of Serbia, Belgrade, RS, <sup>2</sup>Institute of oncology and radiology, Belgrade, RS
- 09:00 - 09:00 **124P - Talazoparib in Local Advanced or Metastatic Breast Cancer Patients: Experience from an Early Access Program in Turkey**  
M.A.N. Sendur<sup>1</sup>, B. Cakar<sup>2</sup>, M. Hızal<sup>3</sup>, E. Eraslan<sup>4</sup>, S. Aksoy<sup>5</sup>, S. Paydas<sup>6</sup>, N. Demir<sup>7</sup>, F. Sen<sup>8</sup>, G. Bulut<sup>9</sup>, K. Oruc<sup>10</sup>, B. Oyan Uluc<sup>11</sup>, N. Ozdemir<sup>12</sup>, A. Sakin<sup>13</sup>, D. Erdem<sup>14</sup>, M. Ozkan<sup>15</sup>, U. Disel<sup>16</sup>, F. Ekinici<sup>17</sup>, I. Okten<sup>18</sup>, L. Ozer<sup>11</sup>, E. Gokmen<sup>19</sup>, <sup>1</sup>Ankara Yıldırım Beyazıt University, Ankara, TR, <sup>2</sup>Ege University, İzmir, TR, <sup>3</sup>Ankara City Hospital, Ankara, TR, <sup>4</sup>Abdurrahman Yurtaslan Ankara Onkology Education and Research Hospital, Ankara, TR, <sup>5</sup>Hacettepe University Faculty of Medicine, Ankara, TR, <sup>6</sup>Cukurova University Faculty of Medicine, Adana, TR, <sup>7</sup>Medicana Sivas Hospital, Sivas, TR, <sup>8</sup>Avrasya Hospital, Istanbul, TR, <sup>9</sup>Necip Faz City Hospital Kahramanmaras, Kahramanmaras, TR, <sup>10</sup>Istanbul University - Cerrahpasa Faculty of Medicine, Istanbul, TR, <sup>11</sup>Acibadem University Faculty of Medicine, Istanbul, TR, <sup>12</sup>Ankara Numune Education and Research Hospital, Ankara, TR, <sup>13</sup>Yuzuncu Yil University Faculty of Medicine, Van, TR, <sup>14</sup>Medical Park Hospital, Samsun, TR, <sup>15</sup>Erciyes University Medical Faculty M.Kemal Dedeman, Oncology Hospital, Kayseri, TR, <sup>16</sup>Acibadem Adana Hastanesi, Adana, TR, <sup>17</sup>MCBU-Manisa Celal Bayar University - Faculty of Medicine, Manisa, TR, <sup>18</sup>S.B. Istanbul Medeniyet Universitesi - Goztepe Egitim Ve Arastirma Hastanesi, Istanbul, TR, <sup>19</sup>Ege University Medical School, Izmir, TR
- 09:00 - 09:00 **125TiP - SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (Trial in Progress)**  
A. Okines<sup>1</sup>, V. Kang<sup>2</sup>, L.N. Walker<sup>3</sup>, P. Pohlmann<sup>4</sup>, <sup>1</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB, <sup>2</sup>Seagen Inv., Bothell, US, <sup>3</sup>Seattle Genetics, Inc., Seattle, US, <sup>4</sup>Lombardi Cancer Center Georgetown University, Washington, US
- 09:00 - 09:00 **126TiP - HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable**

**locally-advanced or metastatic HER2+ breast cancer**

S. Hurvitz<sup>1</sup>, N. Harbeck<sup>2</sup>, L. Vahdat<sup>3</sup>, A. Wolff<sup>4</sup>, S. Tolaney<sup>5</sup>, S. Loi<sup>6</sup>, N. Masuda<sup>7</sup>, J. O'Shaughnessy<sup>8</sup>, D. Xie<sup>9</sup>, L.N. Walker<sup>10</sup>, E. Rustia<sup>11</sup>, V. Borges<sup>12</sup>, <sup>1</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>2</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Johns Hopkins University, Baltimore, US, <sup>5</sup>Dana Farber Cancer Institute, Boston, US, <sup>6</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>7</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>8</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>9</sup>Seagen Inc, Bothell, US, <sup>10</sup>Seattle Genetics, Inc., Seattle, US, <sup>11</sup>Seattle Genetics Inc, Bothell, US, <sup>12</sup>University of Colorado Cancer Center, Lone Tree, US

09:00 - 09:00

**127TiP - Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravnansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2- BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC)**

K. Miller<sup>1</sup>, L. Emens<sup>2</sup>, S. Tolaney<sup>3</sup>, S. Hurvitz<sup>4</sup>, E. Hamilton<sup>5</sup>, V. Paton<sup>6</sup>, A. Hannah<sup>6</sup>, V. Boni<sup>7</sup>, <sup>1</sup>Indiana University Simon Cancer Center, Indianapolis, US, <sup>2</sup>UPMC Hillman Cancer Center, Pittsburgh, US, <sup>3</sup>Dana Farber Cancer Institute, Boston, US, <sup>4</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>5</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>6</sup>CytomX Therapeutics, South San Francisco, US, <sup>7</sup>Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

09:00 - 09:00

**128TiP - HER2CLIMB-04: Phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases (Trial in Progress)**

E. Hamilton<sup>1</sup>, J. Ramos<sup>2</sup>, C. Zhang<sup>2</sup>, I. Krop<sup>3</sup>, <sup>1</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>2</sup>Seattle Genetics, Inc., Seattle, US, <sup>3</sup>Dana Farber Cancer Institute, Boston, US

09:00 - 09:00

**129TiP - Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA**

A. Llombart Cussac<sup>1</sup>, J.M. Pérez-García<sup>2</sup>, S. Blanch<sup>3</sup>, P. Tolosa<sup>4</sup>, M. Ruiz Borrego<sup>5</sup>, M. Gion Cortes<sup>6</sup>, A. Fernández<sup>7</sup>, A. Urruticoechea<sup>8</sup>, E. Galve<sup>9</sup>, J. Cueva Banuelos<sup>10</sup>, J. Ponce<sup>11</sup>, J.L. Alonso<sup>12</sup>, M. Capelán<sup>13</sup>, E. Martínez<sup>14</sup>, B. Bermejo De Las Heras<sup>15</sup>, B. Rojas<sup>16</sup>, T. Martos<sup>17</sup>, A. López<sup>18</sup>, F. Gómez-Peralta<sup>19</sup>, J. Cortés<sup>20</sup>, <sup>1</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>2</sup>International Breast Cancer Center (IBCC), Quiron Group, Barcelona, ES, <sup>3</sup>Oncology Valencian Institute, Valencia, ES, <sup>4</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>5</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>6</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>7</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>8</sup>Private Practice - Urruticoechea, Barcelona, ES, <sup>9</sup>Hospital Universitario Basurto (OSI Bilbao-Basurto), Bilbao, ES, <sup>10</sup>CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>11</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>12</sup>Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, El Palmar, ES, <sup>13</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>14</sup>Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, ES, <sup>15</sup>Hospital

Clinico Universitario de Valencia, Valencia, ES, <sup>16</sup>HM CIOCC, Madrid, ES, <sup>17</sup>Hospital del Mar, Barcelona, ES, <sup>18</sup>University Hospital of León, León, ES, <sup>19</sup>Hospital General de Segovia, Segovia, ES, <sup>20</sup>Vall d'Hebron University Hospital, Barcelona, ES

- 09:00 - 09:00 **130TiP - SOLTI-1303 PATRICIA II randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype**
- E. Ciruelos<sup>1</sup>, A. Garcia<sup>2</sup>, J. Cortés<sup>3</sup>, S. Pernas Simon<sup>4</sup>, E. Garate<sup>5</sup>, M. Melé<sup>6</sup>, Á. Montaña<sup>7</sup>, N. Martinez-Jañez<sup>8</sup>, M. Oliveira<sup>9</sup>, J. De La Haba-Rodríguez<sup>10</sup>, E. Vega<sup>11</sup>, A. Perello Martorell<sup>12</sup>, B. Bermejo De Las Heras<sup>13</sup>, B. Cantos Sanchez De Ibarquen<sup>14</sup>, E. Martínez<sup>15</sup>, E. Vila Navarro<sup>16</sup>, T. Pascual<sup>17</sup>, X. González-Farré<sup>18</sup>, P. Villagrasa<sup>19</sup>, A. Prat<sup>17</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>5</sup>Hospital de Basurto, Bilbao, ES, <sup>6</sup>Hospital Universitari Sant Joan de Reus, Reus, ES, <sup>7</sup>Hospital Universitario Virgen del Rocío, Sevilla, ES, <sup>8</sup>Hospital Universitario Ramón y Cajal. GEICAM Breast Cancer Group, Madrid, ES, <sup>9</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>10</sup>Hospital Universitario Reina Sofía. GEICAM, Spanish Breast Cancer Group, Córdoba, ES, <sup>11</sup>HM CIOCC, Madrid, ES, <sup>12</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>13</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>14</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, <sup>15</sup>Consortio Hospitalario Provincial de Castellón, Castellón de la Plana, ES, <sup>16</sup>SOLTI Grupo Espanol de Estudio, Barcelona, ES, <sup>17</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>18</sup>Hospital General de Catalunya, Sant Cugat del Vallés, ES, <sup>19</sup>SOLTI Breast Cancer Research Group, Barcelona, ES
- 09:00 - 09:00 **131TiP - PRO B - a randomized controlled trial to evaluate the effect of a digital patient-reported outcome monitoring in metastatic breast cancer patients**
- M. Karsten<sup>1</sup>, T. Pross<sup>1</sup>, F. Kühn<sup>2</sup>, J.-U. Blohmer<sup>3</sup>, M. Rose<sup>1</sup>, F. Fischer<sup>1</sup>, C. Breidenbach<sup>4</sup>, U. Grittner<sup>1</sup>, P. Gebert<sup>1</sup>, J. Ferencz<sup>5</sup>, L. Pauler<sup>5</sup>, G. Matthesius<sup>6</sup>, J. Lenz<sup>7</sup>, J. Rocabado<sup>7</sup>, L. Straubing<sup>8</sup>, M. Du Bois<sup>8</sup>, C. Kowalski<sup>4</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>3</sup>St. Gertrauden-Krankenhaus, Berlin, DE, <sup>4</sup>Deutsche Krebsgesellschaft e.V., Berlin, DE, <sup>5</sup>OnkoZert, Neu-Ulm, DE, <sup>6</sup>BARMER, Berlin, DE, <sup>7</sup>DAK-Gesundheit, Hamburg, DE, <sup>8</sup>BKK-VBU, Berlin, DE
- 09:00 - 09:00 **Supportive care and survivorship**
- 09:00 - 09:00 **132P - The psychological impact of the COVID-19 pandemic on patients with early breast cancer**
- S. Almeida<sup>1</sup>, D. Frasilho<sup>1</sup>, G. Cotovio<sup>2</sup>, F. Viana<sup>2</sup>, B. Sousa<sup>1</sup>, J. Oliveira<sup>2</sup>, J. Mattson<sup>3</sup>, C. Marzorati<sup>4</sup>, I. Roziner<sup>5</sup>, E. Karademas<sup>6</sup>, E. Kolokotroni<sup>6</sup>, G. Stamatakos<sup>6</sup>, K. Mazzocco<sup>7</sup>, R. Pat-Horenczyk<sup>8</sup>, P. Poikonen-Saksela<sup>3</sup>, F. Cardoso<sup>9</sup>, A. Oliveira-Maia<sup>2</sup>, <sup>1</sup>Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, <sup>2</sup>Champalimaud Clinical and Research Centre - Champalimaud Centre for the Unknown, Lisbon, PT, <sup>3</sup>Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FI, <sup>4</sup>European Institute of Oncology, Milan, IT, <sup>5</sup>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, IL,

<sup>6</sup>Institute of Communication and Computer Systems, National Technical University of Athens, Athens, GR, <sup>7</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>8</sup>The Hebrew University of Jerusalem, Tel Aviv, IL, <sup>9</sup>Champalimaud Foundation Cancer Center, Lisbon, PT

- 09:00 - 09:00 **133P - Breast Cancer in Young Women (BCYW). Different entity or different needs?**  
J.C. Sánchez<sup>1</sup>, B. Nunez Garcia<sup>1</sup>, M. Mendez Garcia<sup>2</sup>, M. Blanco Clemente<sup>3</sup>, A. Morito Aguilar<sup>3</sup>, B. De La Puente Orteu<sup>2</sup>, C. De La Fuente<sup>1</sup>, D. Suárez<sup>1</sup>, M. Provencio Pulla<sup>2</sup>, B. Cantos Sanchez De Ibarquen<sup>4</sup>, <sup>1</sup>Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES, <sup>2</sup>Hospital Puerta de Hierro-Majadahonda, Madrid, ES, <sup>3</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES
- 09:00 - 09:00 **134P - Towards tailored follow-up care for breast cancer survivors: cluster analyses based on symptom burden**  
K. De Ligt<sup>1</sup>, B. De Rooij<sup>2</sup>, I. Walraven<sup>3</sup>, M. Heins<sup>4</sup>, S. Siesling<sup>2</sup>, J. Korevaar<sup>4</sup>, L. Van De Poll-Franse<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Comprehensive Cancer Organization, Utrecht, NL, <sup>3</sup>Radboudumc, Nijmegen, NL, <sup>4</sup>Netherlands Institute of Health Services Research, Utrecht, NL
- 09:00 - 09:00 **135P - Relationship between low muscle mass pre-chemotherapy with hematological toxicity in breast cancer patients after 3 cycles of chemotherapy**  
A. Kurniawan<sup>1</sup>, D. Halim<sup>2</sup>, C. Jodhinata<sup>2</sup>, P. Lukito<sup>2</sup>, R. Hatma<sup>3</sup>, A. Adisasmita<sup>3</sup>, S. Panigoro<sup>4</sup>, N. Sutandyo<sup>4</sup>, T. Tamin<sup>4</sup>, F. Witjaksono<sup>4</sup>, R. Sumantri<sup>5</sup>, D. Rivami<sup>2</sup>, <sup>1</sup>Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID, <sup>2</sup>Faculty of Medicine, Pelita Harapan University, Tangerang, ID, <sup>3</sup>Faculty of Public Health, Universitas Indonesia, Depok, ID, <sup>4</sup>Faculty of Medicine, Universitas Indonesia, Jakarta, ID, <sup>5</sup>Faculty of Medicine, Padjadjaran University, Bandung, ID
- 09:00 - 09:00 **136P - The incidence and prognostic impact of obesity in young Egyptian breast cancer patients**  
A. Athman Omar<sup>1</sup>, A.M. Amin Darwish<sup>2</sup>, <sup>1</sup>Alexandria clinical oncology department, Alexandria, EG, <sup>2</sup>University of Alexandria - Faculty of Medicine, Alexandria, EG
- 09:00 - 09:00 **137P - Survivorship care plan for breast cancer patients: an intensive follow-up is still useless?**  
G. Cortesi, F. Piacentini, L. Moscetti, M. Barbolini, C. Nasso, C. Isca, R. D'Onofrio, M. Dominici, C. Omarini, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT
- 09:00 - 09:00 **138P - Absenteeism at work in breast cancer patients undergoing therapy**  
N. Mejri<sup>1</sup>, Y. Berrazega<sup>2</sup>, H. Rachdi<sup>2</sup>, I. Harhira<sup>2</sup>, N. Daoud<sup>2</sup>, H. Boussen<sup>3</sup>, <sup>1</sup>Hopital Abderrahmane Mami de Pneumophistologie, Ariana, TN, <sup>2</sup>Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, <sup>3</sup>Abderrahmen Mami Hospital, Ariana, TN

09:00 - 09:00

**140P - How breast cancer recurrences are found? - a real-world, prospective cohort study**

S. Myller<sup>1</sup>, A. Jukkola<sup>2</sup>, A. Jääskeläinen<sup>3</sup>, N. Roininen<sup>3</sup>, P. Karihtala<sup>4</sup>, <sup>1</sup>University of Oulu, FBMM, Oulu, FI, <sup>2</sup>Tampere University Hospital and Tampere University, Tampere, FI, <sup>3</sup>Oulu University Hospital and University of Oulu, Oulu, FI, <sup>4</sup>Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, FI

09:00 - 09:00 **141P - Cognitive impairment among breast cancer patients receiving endocrine treatment: a comparative study between aromatase inhibitors and tamoxifen**

I. Ben Abdallah<sup>1</sup>, H. Rachdi<sup>2</sup>, N. Mejri<sup>3</sup>, Y. Berrazega<sup>2</sup>, H. El Benna<sup>2</sup>, N. Daoud<sup>2</sup>, S. Laabidi<sup>4</sup>, H. Boussen<sup>5</sup>, <sup>1</sup>University of Tunis El Manar - Faculty of Medicine, Tunis, TN, <sup>2</sup>Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, <sup>3</sup>Hopital Abderrahmane Mami de Pneumophistologie, Ariana, TN, <sup>4</sup>Hopital Abderrahmen Mami de Pneumo-Phistologie, Ariana, TN, <sup>5</sup>Abderrahmen Mami Hospital, Ariana, TN

09:00 - 09:00 **142P - Bone mineral density (BMD) after three years of adjuvant zoledronic acid (ZA) in postmenopausal oestrogen receptor positive (ER+) early breast cancer (EBC): an observational single centre study.**

C. Harper-Wynne<sup>1</sup>, R. Burcombe<sup>2</sup>, <sup>1</sup>Maidstone Hospital Maidstone & Tunbridge NHS TRUST, Maidstone, GB, <sup>2</sup>Kent Oncology Centre, QQ, GB

09:00 - 09:00 **143P - Fertility rates in Young Breast Cancer Patients (YBCP) and evolution. A new challenge**

M. Mendez Garcia<sup>1</sup>, B. Nunez Garcia<sup>2</sup>, M. Blanco Clemente<sup>3</sup>, J.C. Sánchez<sup>2</sup>, S. Herrero<sup>2</sup>, V. Engels<sup>2</sup>, G. Visedo<sup>1</sup>, M. Martinez Cutillas<sup>1</sup>, M. Provencio Pulla<sup>1</sup>, B. Cantos Sanchez De Ibarquen<sup>4</sup>, <sup>1</sup>Hospital Puerta de Hierro-Majadahonda, Madrid, ES, <sup>2</sup>Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES, <sup>3</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES

09:00 - 09:00 **144P - Cognitive complaints among Tunisian breast cancer patients receiving adjuvant aromatase-inhibitors**

I. Ben Abdallah<sup>1</sup>, H. Rachdi<sup>2</sup>, D. Dhib<sup>1</sup>, N. Mejri<sup>3</sup>, Y. Berrazega<sup>2</sup>, H. El Benna<sup>2</sup>, N. Daoud<sup>2</sup>, S. Laabidi<sup>4</sup>, H. Boussen<sup>5</sup>, <sup>1</sup>University of Tunis El Manar - Faculty of Medicine, Tunis, TN, <sup>2</sup>Hopital Abderrahmane Mami de Pneumophistologie, Tunis, TN, <sup>3</sup>Hopital Abderrahmane Mami de Pneumophistologie, Ariana, TN, <sup>4</sup>Hopital Abderrahmen Mami de Pneumo-Phistologie, Ariana, TN, <sup>5</sup>Abderrahmen Mami Hospital, Ariana, TN

09:00 - 09:00 **145P - The Potential Benefits of Internet-based Cognitive Behavioural Therapy for Improving Psychosocial Aspects, Sexual Functioning, And Treatment-induced Menopausal Symptoms Among Breast Cancer Survivors: Systematic Review and Meta-analysis**

B.P. Putra<sup>1</sup>, F.N. Putra<sup>2</sup>, <sup>1</sup>Dr. Soetomo Hospital-Airlangga University Medical School, Surabaya, ID, <sup>2</sup>Universitas Airlangga, Surabaya, ID

09:00 - 09:00 **146P - Impact of Breast Cancer Treatment on Sexual Health in Pre-Menopausal Women**

S. Garg, L. Enny, K. Singh, P. Ramakant, A. Mishra, KGMU - King George's Medical

University, Lucknow, IN

- 09:00 - 09:00 **147P - When a single G-CSF administration is better than longer duration: example in patients treated by eribulin**  
A. Schmitt<sup>1</sup>, M. Reda<sup>1</sup>, P. Macaire<sup>1</sup>, H. Bellio<sup>1</sup>, L. Uwer<sup>2</sup>, S.M. Ilie<sup>3</sup>, V. Lorgis<sup>4</sup>, A. Hennequin<sup>1</sup>, S. Ladoire<sup>1</sup>, E. Rederstorff<sup>1</sup>, P. Fumoleau<sup>5</sup>, N. Isambert<sup>1</sup>, N. Bonnin<sup>6</sup>, B. You<sup>6</sup>, G. Freyer<sup>7</sup>, I. Desmoulins<sup>1</sup>, <sup>1</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>2</sup>Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, <sup>3</sup>Institutul Oncologic "Profesor Doctor Alexandru Trestioreanu", Bucharest, RO, <sup>4</sup>Polyclinique Du Parc Drevon, Dijon, FR, <sup>5</sup>Institut Curie, Paris, FR, <sup>6</sup>Ch Lyon Sud, Pierre Benite, FR, <sup>7</sup>Lyon Sud Hospital Center - HCL, Pierre Benite, FR
- 09:00 - 09:00 **148P - Breast Cancer as Second Primary Malignancy in Cancer Survivors- Experience from a Tertiary Cancer Center in India**  
R. Joseph P, A. T M, G. Narayanan, S. Nair, RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN
- 09:00 - 09:00 **149P - Restricted mean survival time (RMST): a new tool for time to event analysis in young breast cancer patients (YBCP)**  
J.C. Sánchez<sup>1</sup>, M. Mendez Garcia<sup>2</sup>, B. Nunez Garcia<sup>1</sup>, M. Blanco Clemente<sup>3</sup>, J. Mucientes<sup>1</sup>, M. López Valcárcel<sup>1</sup>, R. Aguado<sup>3</sup>, A. Royuela<sup>1</sup>, M. Provencio Pulla<sup>2</sup>, B. Cantos Sanchez De Ibarquen<sup>4</sup>, <sup>1</sup>Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES, <sup>2</sup>Hospital Puerta de Hierro-Majadahonda, Madrid, ES, <sup>3</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES
- 09:00 - 09:00 **150P - Expanding The Potential Benefits of Cognitive Behavioural Therapy for Insomnia in Improving Psychological Functioning And Quality of Life Among Breast Cancer Survivors with Insomnia: A Meta-analysis of Randomized Controlled Trials**  
B.P. Putra<sup>1</sup>, F.N. Putra<sup>2</sup>, <sup>1</sup>Dr. Soetomo Hospital-Airlangga University Medical School, Surabaya, ID, <sup>2</sup>Universitas Airlangga, Surabaya, ID
- 09:00 - 09:00 **General interest**
- 09:00 - 09:00 **151P - Impact of germline BRCA (gBRCA) mutation (m) status on clinical characteristics and patterns of care among women with early breast cancer (eBC): an analysis of the observational prospective CANTO cohort**  
A. Bertaut<sup>1</sup>, J. Blanc<sup>1</sup>, B. Pistilli<sup>2</sup>, A. Dhaini Merimeche<sup>3</sup>, O. Rigal<sup>4</sup>, C. Coutant ( Coutant )<sup>5</sup>, M. Fournier<sup>6</sup>, C.C. Jouannaud ( Jouannaud )<sup>7</sup>, P. Soulie<sup>8</sup>, F. Lerebours<sup>9</sup>, P. Cottu<sup>10</sup>, O. Tredan<sup>11</sup>, L. Vanlemmens<sup>12</sup>, C. Levy<sup>13</sup>, M.-A. Mouret-Reynier<sup>14</sup>, M. Campone<sup>15</sup>, A.-L. Martin<sup>16</sup>, A. Jacquet Jacquet<sup>16</sup>, N. Briot<sup>1</sup>, I. Vaz-Luis<sup>2</sup>, <sup>1</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>Centre Alexis Vautrin, NANCY, FR, <sup>4</sup>Centre Henri Becquerel, ROUEN, FR, <sup>5</sup>Centre Georges Francois Leclerc, Dijon, FR, <sup>6</sup>Institut Bergonié, BORDEAUX, FR, <sup>7</sup>Institut Jean Godinot, Reims, FR, <sup>8</sup>Institut de Cancérologie de L'ouest -Paul Papin, ANGERS, FR, <sup>9</sup>Hôpital René Huguenin - Institut

Curie, St. Cloud, FR, <sup>10</sup>Institut Curie, Paris, FR, <sup>11</sup>Centre Léon Bérard, Lyon, FR, <sup>12</sup>Centre Oscar Lambret, Lille, FR, <sup>13</sup>Centre Francois Baclesse, Caen, FR, <sup>14</sup>Centre Jean-Perrin, Clermont Ferrand, FR, <sup>15</sup>Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, SAINT-HERBLAIN, FR, <sup>16</sup>Unicancer, Paris, FR

- 09:00 - 09:00 **152P - Analysis of patient access to breast cancer drugs in the USA and Europe with a focus on the UK and Ireland.**  
R. McLaughlin<sup>1</sup>, D. O'Reilly<sup>2</sup>, C. Ronayne<sup>2</sup>, E. Barrett<sup>1</sup>, R. Kalachand<sup>1</sup>, A.M. De Frein<sup>3</sup>, B. Macanovic<sup>2</sup>, R. Connolly<sup>2</sup>, D. Power<sup>2</sup>, R. Bambury<sup>2</sup>, S. Reilly<sup>2</sup>, D. Collins<sup>2</sup>, <sup>1</sup>University Hospital Limerick, Limerick, IE, <sup>2</sup>Cork University Hospital, Cork, IE, <sup>3</sup>National Cancer Control Programme, Dublin, IE
- 09:00 - 09:00 **153P - Prevalence and survival of stage IV male breast cancer: a SEER database analysis**  
P. Miguel-Semedo<sup>1</sup>, C. Costa Lopes Pinto<sup>2</sup>, L.A. Marques Da Costa<sup>3</sup>, A. Ferreira<sup>4</sup>, <sup>1</sup>HSM - Hospital Santa Maria - Centro Hospitalar Universitario de Lisboa Norte E.P.E., Lisbon, PT, <sup>2</sup>Centro Hospitalar Lisboa Norte - Hospital Sta Maria (HSM-CHLN), Lisbon, PT, <sup>3</sup>HSM - Hospital Santa Maria - Centro Hospitalar de Lisboa Norte E.P.E., Lisbon, PT, <sup>4</sup>Champalimaud Foundation, Lisbon, PT
- 09:00 - 09:00 **154P - Impact Of Covid-19 On Diagnosis And Surgical Care Of Patients With Breast Cancer.**  
A. L., D.V. Kumar, P. K, J. Dharmarajan, S. Soman, H. Jayamohan, A. Vinod, Amrita Institute of Medical Sciences, Kochi/Cochin, IN
- 09:00 - 09:00 **155P - Profile of pathogenic mutations and evaluation of germline genetic testing criteria in consecutive breast cancer patients treated at a North Indian tertiary care center**  
A. Mittal<sup>1</sup>, R. Pramanik<sup>1</sup>, A. Gogia<sup>1</sup>, A. Batra<sup>1</sup>, A. Jha<sup>1</sup>, L. Kumar<sup>1</sup>, S. Deo<sup>1</sup>, S. Bhorival<sup>1</sup>, K. Deb<sup>1</sup>, E. Dhamija<sup>1</sup>, V. Ramprasad<sup>1</sup>, O. Olopade<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>University of Chicago, Chicago, US
- 09:00 - 09:00 **156P - The Effectiveness of Intraoperative Administration Of Both Radioactive Isotope And Blue Dye Without Pre-Surgery Gamma Imaging In Comparison With The Conventional Technique For Sentinel Node Biopsy.**  
D.V. Kumar, A. L, R. Aggarwal, P. Sundaram, Amrita Institute of Medical Sciences, Kochi/Cochin, IN
- 09:00 - 09:00 **157P - Racial Diversity and Reporting in FDA registration trials for Breast Cancer from 2006-21**  
M. Lythgoe<sup>1</sup>, J. Krell<sup>1</sup>, L. Kenny<sup>2</sup>, A. Khaki<sup>3</sup>, <sup>1</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>2</sup>Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, GB, <sup>3</sup>University of Washington, Seattle, US
- 09:00 - 09:00 **158P - Obstructive sleep apnea and breast cancer incidence: a systematic review and meta-analysis**  
N. Tan<sup>1</sup>, D. Yap<sup>1</sup>, B.K.J. Tan<sup>1</sup>, Y.H. Teo<sup>1</sup>, V. Tan<sup>2</sup>, A. See<sup>3</sup>, S.T. Toh<sup>3</sup>, <sup>1</sup>NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG,

<sup>2</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>3</sup>Singapore General Hospital, Singapore, SG

- 09:00 - 09:00 **159P - Obesity and oral contraceptives reduce the preventive benefit of breastfeeding against breast cancer in Mexican women**  
H. Rodriguez Gutierrez<sup>1</sup>, A. Guerra Cepeda<sup>2</sup>, R. Cerda Flores<sup>2</sup>, O. Solis Coronado<sup>1</sup>, D. Reding Hernandez<sup>1</sup>, J. Gonzalez Guerrero<sup>3</sup>, O. Vidal Gutierrez<sup>1</sup>, D. Perez Ibanez<sup>1</sup>, M. Garza Rodriguez<sup>1</sup>, <sup>1</sup>University Autonomous of Nuevo Leon, MONTERREY, MX, <sup>2</sup>University Autonomous of Nuevo Leon, MONTERREY, NUEVO LEON, MX, <sup>3</sup>University Autonomous of Nuevo Leon, MONTERREY, NUEVO LEON, MX
- 09:00 - 09:00 **160P - Distribution of mammographic density and its relationship to age in men**  
H. Lee, University Of Pennsylvania, Philadelphia, US
- 09:00 - 09:00 **161P - Impact of HIV infection on mortality rate and overall survival of women with breast cancer in a Haitian cancer clinic.**  
J.J. Bernard, L. Alexis, D.P. Gilbert, V.J. Degennaro, Innovating Health International Cancer Program, Port-au-Prince, HT
- 09:00 - 09:00 **162P - Unique challenges and Outcomes of Young Breast Cancers from a tertiary care cancer centre in India**  
J. Bajpai<sup>1</sup>, V. Pradeep<sup>1</sup>, R. Nandhana<sup>2</sup>, S. Mohanty<sup>1</sup>, Q. Chougale<sup>1</sup>, M. Engineer<sup>1</sup>, S. Rath<sup>1</sup>, S. Joshi<sup>1</sup>, T. Wadasadawala<sup>1</sup>, P. Popat<sup>1</sup>, R. Pathak<sup>1</sup>, S. Gulia<sup>1</sup>, J. Ghosh<sup>1</sup>, P. Bhargava<sup>3</sup>, S. Srinivas<sup>1</sup>, T. Shet<sup>1</sup>, R. Sarin<sup>1</sup>, R. Badwe<sup>4</sup>, S. Gupta<sup>3</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>GSL Medical College & General Hospital, Rajahmundry, IN, <sup>3</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>4</sup>Tata Memorial Centre, Mumbai, IN
- 09:00 - 09:00 **163P - Epidemiological profile of breast cancer in Morocco: first results from the Reference Center for Reproductive Health in Kenitra**  
F. Aboulhoda<sup>1</sup>, A. Soulaymani<sup>1</sup>, F. Bejja<sup>1</sup>, A. Mokhtari<sup>1</sup>, H. Hami<sup>2</sup>, <sup>1</sup>Faculty of Science, Kenitra, MA, <sup>2</sup>Ibn Tofail University, Kenitra, MA
- 09:00 - 09:00 **164P - Usefulness of Positron Emission Tomography for Determination of Axillary Metastasis of Breast Cancer**  
G. Pöstecki<sup>1</sup>, A. Güreşin<sup>2</sup>, S. Güler<sup>2</sup>, N. Cantürk<sup>2</sup>, <sup>1</sup>Kocaeli Devlet Hastanesi, Izmit, TR, <sup>2</sup>Kocaeli University, Kocaeli, TR
- 09:00 - 09:00 **165P - Comparison of male and female breast cancer in reference hospital in Mexico**  
G. Sánchez<sup>1</sup>, A. Gutierrez<sup>2</sup>, J.C. Jiménez<sup>3</sup>, R. Correa<sup>4</sup>, J. Alegria Banos<sup>5</sup>, R. Grajales Alvarez<sup>6</sup>, <sup>1</sup>Hospital de Oncología, Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social, Ciudad de Mexico, MX, <sup>2</sup>58 Regional Hospital IMSS, Leon, MX, <sup>3</sup>National Autonomous University of Mexico, Ciudad de Mexico, MX, <sup>4</sup>IMSS - Centro Medico Nacional Siglo XXI - Hospital de Oncologia, Ciudad de Mexico, MX, <sup>5</sup>Hospital Medica Sur, Ciudad de Mexico, MX, <sup>6</sup>Centro Medico Nacional Siglo XXI Hospital de Oncologia, Ciudad de Mexico, MX

- 09:00 - 09:00 **166P - Breast cancer at the age of 90 and above**  
J. Barinoff, K.C.K. Ho, J. Schikschneit, U. St.Hilaire, K. Brandt, M.Y. Vornhecke, St. Gertrauden-Krankenhaus, Berlin, DE
- 09:00 - 09:00 **167P - Reproductive factors and hormonal contraceptives in relation with breast cancer histopathology.**  
A. Malek<sup>1</sup>, E. Gusbi<sup>2</sup>, M. Grain<sup>3</sup>, M. Eddeb<sup>3</sup>, M. Erzeghi<sup>3</sup>, H. Ahmed<sup>4</sup>, <sup>1</sup>Airport Road Polyclinic, Tripoli, LY, <sup>2</sup>Biotechnology And research Center, Tripoli, LY, <sup>3</sup>Tripoli University Hospital, Tripoli, LY, <sup>4</sup>Tripoli University, Tripoli, LY
- 09:00 - 09:00 **168P - Danish women favour hypothetical breast cancer screening with harms, but no benefits**  
E.-L. Røssell<sup>1</sup>, A. Bo<sup>1</sup>, S. Borgquist<sup>2</sup>, T. Grønberg<sup>1</sup>, I. Kristiansen<sup>3</sup>, L. Scherer<sup>4</sup>, H. Støvring<sup>1</sup>, <sup>1</sup>Aarhus Universitet, Aarhus, DK, <sup>2</sup>Aarhus University Hospital, Aarhus, DK, <sup>3</sup>Oslo University, Oslo, NO, <sup>4</sup>University of Colorado, Denver, US
- 09:00 - 09:00 **169P - Evaluation of the effectiveness of telephone consultations and the level of satisfaction of patients attending the Unidad Docente Asistencial de Mastología [Mastology Care Teaching Unit] using this method during the COVID health emergency.**  
N. Camejo<sup>1</sup>, C. Castillo<sup>2</sup>, N. Artagaveytia<sup>1</sup>, D. Amarillo<sup>1</sup>, F. Vitureira<sup>1</sup>, F. Rodriguez<sup>1</sup>, L. Delgado<sup>1</sup>, <sup>1</sup>Hospital de Clinicas Dr. Manuel Quintela, Montevideo, UY, <sup>2</sup>Hospital de Clinicas, Montevideo, UY
- 09:00 - 09:00 **170P - Pattern and prognosis of fatal cardiac events in locoregional and distant stages in female breast cancer patients: SEER- based analysis**  
M.H.O. Safi<sup>1</sup>, D. Trapani<sup>2</sup>, M. Alradhi<sup>3</sup>, A. Al-Danakh<sup>4</sup>, X. Shan<sup>5</sup>, F. Ping<sup>5</sup>, A. Al-Masni<sup>6</sup>, Y. Jamal<sup>1</sup>, N. Al-Sabai<sup>1</sup>, A. Al-Dhaibani<sup>1</sup>, A. Al-Samawi<sup>1</sup>, M. Al-Sameai<sup>1</sup>, A. Al-Sharabi<sup>1</sup>, J. Liu<sup>4</sup>, <sup>1</sup>Dalian Medical University, Dalian, CN, <sup>2</sup>Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Second affiliated hospital of Dalian medical university, Dalian city, CN, <sup>4</sup>The first affiliated hospital of Dalian medical university, Dalian city, YE, <sup>5</sup>The first affiliated hospital of Dalian medical university, Dalian city, CN, <sup>6</sup>Princess Rahma Pediatric Hospital, Irbid, JO
- 09:00 - 09:00 **171P - Validity and Reliability Tests of the UNS-CASKQ14 Questionnaire about the Quality and Compliance of Breast Cancer Survivors amid the Covid-19 Pandemic**  
W. Soewoto, M.D. Putra, G. Putra, Medical Faculty of Sebelas Maret University, Surakarta, ID
- 09:00 - 09:00 **172P - Men with Breast Cancer - Biology and Stage at Diagnosis in Eastern Europe - Balkan Collaborative Project**  
M. Vasileva-Slaveva<sup>1</sup>, A. Piciu<sup>2</sup>, N. Polocoser<sup>3</sup>, A.-A. Kovendi<sup>3</sup>, Z. Inic<sup>4</sup>, M. Jevric<sup>4</sup>, A. Yordanov<sup>5</sup>, S. Volovat<sup>6</sup>, A. Konsoulova<sup>7</sup>, <sup>1</sup>Alexandrovska University Hospital, Sofia, BG, <sup>2</sup>University of Medicine and Pharmacy, Cluj-Napoca, RO, <sup>3</sup>Institute of Oncology, Cluj-Napoca, RO, <sup>4</sup>Institute of oncology and radiology, Belgrade, RS, <sup>5</sup>Medical University Pleven, Pleven, BG, <sup>6</sup>University of Medicine and Pharmacy "Gr.T.Popa", Iasi, RO, <sup>7</sup>Complex Oncological Center Burgas, Burgas, BG

- 09:00 - 09:00 **173P - Quality Indicators of Treatment of Breast Cancer in Bulgaria**  
M. Vasileva-Slaveva<sup>1</sup>, S. Maslyankov<sup>1</sup>, N. Velikova<sup>2</sup>, K. Nedev<sup>2</sup>, I. Georgiev<sup>2</sup>, E. Chupryna<sup>3</sup>, S. Strashilov<sup>4</sup>, A. Yordanov<sup>4</sup>, <sup>1</sup>Alexandrovska University Hospital, Sofia, BG, <sup>2</sup>Acibadem City Clinic, Sofia, BG, <sup>3</sup>Military Medical Academy, Sofia, BG, <sup>4</sup>Medical University Pleven, Pleven, BG
- 09:00 - 09:00 **174P - Breast screening at young age. A real need?**  
B. Nunez Garcia<sup>1</sup>, J.C. Sánchez<sup>1</sup>, M. Blanco Clemente<sup>2</sup>, M. Mendez Garcia<sup>3</sup>, M.C. Vega<sup>1</sup>, S. Carmona<sup>1</sup>, B. De La Puente<sup>1</sup>, A. Morito Aguilar<sup>2</sup>, M. Provencio Pulla<sup>3</sup>, B. Cantos Sanchez De Ibarquen<sup>4</sup>, <sup>1</sup>Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES, <sup>2</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>3</sup>Hospital Puerta de Hierro-Majadahonda, Madrid, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES
- 09:00 - 09:00 **175P - Tumor biology in Young Breast Cancer Patients (YBCP). A different disease?**  
B. Cantos Sanchez De Ibarquen<sup>1</sup>, M. Mendez Garcia<sup>2</sup>, M. Blanco Clemente<sup>3</sup>, B. Nunez Garcia<sup>4</sup>, C. Corbacho<sup>4</sup>, C. Gonzalez Lois<sup>4</sup>, R. Aguado<sup>3</sup>, Y. Garitaonaindia<sup>4</sup>, M. Provencio Pulla<sup>2</sup>, J.C. Sánchez<sup>4</sup>, <sup>1</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, ES, <sup>2</sup>Hospital Puerta de Hierro-Majadahonda, Madrid, ES, <sup>3</sup>Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, ES, <sup>4</sup>Hospital Universitario Puerta de Hierro - (INSALUD), Majadahonda, ES
- 09:00 - 09:00 **176P - Breast Cancer Treatment During The First Wave Of The COVID-19 Pandemic At A UK Centre**  
K. Balachandran<sup>1</sup>, J. Williams<sup>1</sup>, D. Bell<sup>1</sup>, A. Brown<sup>1</sup>, S. Mahmoud<sup>1</sup>, P. Hurhangee<sup>1</sup>, R. Ramakrishnan<sup>1</sup>, S. Cleator<sup>1</sup>, R.C. Coombes<sup>2</sup>, O. Hatcher<sup>1</sup>, F. Rehman<sup>1</sup>, J. Stebbing<sup>2</sup>, L. Kenny<sup>3</sup>, <sup>1</sup>Charing Cross Hospital - Imperial College Healthcare NHS Trust, London, GB, <sup>2</sup>Imperial College London - Hammersmith Hospital, London, GB, <sup>3</sup>Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, GB
- 09:00 - 09:00 **177P - COVID-19 pandemic impact in newly diagnosed breast cancer patients BCP at a 3rd level hospital**  
M.C. Guillen Sacoto<sup>1</sup>, E. Núñez-Manchón<sup>2</sup>, X. Bargalló<sup>3</sup>, B. Adamo<sup>4</sup>, I. Alonso<sup>3</sup>, M. Mollà<sup>3</sup>, M. Vidal<sup>3</sup>, G. Oses González<sup>3</sup>, X. Caparrós<sup>3</sup>, B. Gonzalez-Farre<sup>3</sup>, N. Chic<sup>5</sup>, O. Martínez-Sáez<sup>3</sup>, B. Ubeda<sup>3</sup>, R. Moreno<sup>3</sup>, I. Cebrecos<sup>3</sup>, J. Fontdevila Font<sup>3</sup>, S. Vidal-Sicart<sup>3</sup>, A. Rodríguez<sup>3</sup>, A. Prat<sup>4</sup>, M. Muñoz<sup>3</sup>, <sup>1</sup>IBSAL - Instituto de Investigación Biomédica de Salamanca, Salamanca, ES, <sup>2</sup>Fundació Clínic per la Recerca Biomèdica, Barcelona, ES, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>4</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>5</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES
- 09:00 - 09:00 **178P - Imaging for distant metastasis in local and locally advanced breast cancer: practice and detection rates**  
A. Da Silva Oliveira<sup>1</sup>, M. Menezes<sup>2</sup>, I. Dunoos<sup>2</sup>, R. Cunha<sup>2</sup>, T. Carvalho<sup>2</sup>, E. Bravo<sup>2</sup>, R. Dinis<sup>2</sup>, <sup>1</sup>Hospital Espírito Santo, EPE - Évora, Evora, PT, <sup>2</sup>Hospital Espírito Santo, EPE - Évora, Évora, PT

09:00 - 09:00 **179P - Discordance rates of clinicopathological features in bilateral breast cancer**

A. Aranda-Gutierrez<sup>1</sup>, A. Ferrigno<sup>2</sup>, B. Vaca-Cartagena<sup>3</sup>, F. Gonzalez-Mondellini<sup>4</sup>, A. Becerril-Gaitán<sup>3</sup>, M. Roman-Zamudio<sup>4</sup>, M. Acosta-Sandoval<sup>4</sup>, M. Torres-Leal<sup>4</sup>, C. Treviño-Alanis<sup>4</sup>, H. Diaz-Perez<sup>3</sup>, S. Cardona<sup>3</sup>, C. Villarreal-Garza<sup>3</sup>, <sup>1</sup>TecSalud del Tecnológico de Monterrey, Monterrey, MX, <sup>2</sup>Hospital Zambrano Hellion TecSalud, San Pedro Garza Garcia, MX, <sup>3</sup>Hospital Zambrano Hellion, Tecnológico de Monterrey, San Pedro Garza Garcia, MX, <sup>4</sup>Escuela de Medicina y Ciencias de la Salud, Monterrey, MX

09:00 - 09:00 **180P - Factors associated with late-stage diagnosis of breast cancer among Egyptian women**

H. Ismail<sup>1</sup>, S. Mokhtar<sup>2</sup>, H. El-Mansy<sup>3</sup>, <sup>1</sup>Alexandria University- The High Institute of Public Health, Alexandria, EG, <sup>2</sup>The High Institute of Public Health, Alexandria, EG, <sup>3</sup>Medical Research Institute, El Ibrahmya, EG

16:00 - 17:00	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 1</b>	<b>Channel 1</b>
16:00 - 17:00	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 2</b>	<b>Channel 2</b>
17:30 - 18:30	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 3</b>	<b>Channel 1</b>
17:30 - 18:30	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 4</b>	<b>Channel 2</b>
19:00 - 20:00	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 5</b>	<b>Channel 1</b>
19:00 - 20:00	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 6</b>	<b>Channel 2</b>

06.05.2021

<b>16:00 - 17:00</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 7</b>	<b>Channel 1</b>
<b>16:00 - 17:00</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 8</b>	<b>Channel 2</b>
<b>17:30 - 18:30</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 9</b>	<b>Channel 1</b>
<b>17:30 - 18:30</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 10</b>	<b>Channel 2</b>
<b>19:00 - 20:00</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 11</b>	<b>Channel 1</b>
<b>19:00 - 20:00</b>	<b>Type: Industry Satellite Symposia</b> <b>Title: Industry Satellite symposium 12</b>	<b>Channel 2</b>

07.05.2021

**11:55 - 12:00**    **Type: Opening**    **Channel 1**  
**Title: Welcome to the ESMO Breast Cancer Virtual Meeting 2021**

**12:00 - 12:30**    **Type: Keynote**    **Channel 1**  
**Title: Keynote 1**

12:00 - 12:05    **Introduction by the Chair**

12:05 - 12:30    **Title to be defined**

**12:45 - 14:00**    **Type: Educational session**    **Channel 1**  
**Title: Optimal sequence in metastatic HER2+ breast cancer**  
Chair(s): Lisa Carey, US; Aleix Prat, ES

12:45 - 13:00    **Decision-making in metastatic HER2+ BC in 2021**  
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

13:00 - 13:15    **HER2+ breast cancer: Clinical consequences of biologic heterogeneity**  
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

13:15 - 13:30    **Making a chronic disease of metastatic HER2+ breast cancer: Are any cured?**  
E. Winer, Harvard Medical School, Boston, US

13:30 - 13:45    **Do CNS metastases in HER2+ BC require a different systemic approach?**  
T. Bachelot, Centre Léon Bérard, Lyon, FR

13:45 - 13:55    **Q&A and live discussion**

<b>12:45 - 14:00</b>	<b>Type: Educational session</b> <b>Title: Precision medicine in breast cancer</b> Chair(s): Monica Arnedos, FR; Christos Sotiriou, BE	<b>Channel 3</b>
12:45 - 13:00	<b>cfDNA testing for early detection of breast cancer and breast cancer relapse. Ready for prime time?</b> <u>N. Turner</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
13:00 - 13:15	<b>Genomic profiling for mBC patients: Which techniques? To whom, when and how often?</b> <u>M. Arnedos</u> , Institut Gustave Roussy, Villejuif, FR	
13:15 - 13:30	<b>Is there a role for molecular profiling in early breast cancer?</b>  <u>C. Sotiriou</u> , Institute Jules Bordet, Brussels, BE	
13:30 - 13:45	<b>Epigenetics in breast cancer: The comeback of an old friend?</b> <u>L. Magnani</u> , Imperial College London-South Kensington Campus, London, GB	
13:45 - 13:55	<b>Q&amp;A and live discussion</b>	

**14:15 - 15:30**    **Type: Educational session**    **Channel 1**  
**Title: Neoadjuvant/ adjuvant treatment in triple negative breast cancer**  
 Chair(s): Javier Cortés, ES; Rebecca Dent, SG

14:15 - 14:20    **Live introduction**

14:20 - 14:35    **The role of the immune environment in TNBC**  
R. Salgado, St-Augustinus Ziekenhuis, Wilrijk, BE

14:35 - 14:50    **How to treat patients with early TNBC on Monday morning**  
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

14:50 - 15:05    **The role of immunotherapy in early TNBC**  
P. Schmid, Barts Cancer Institute-Queen Mary University of London, London, GB

15:05 - 15:20    **Potential new drugs with activity in metastatic TNBC**  
J. Cortés, Vall d'Hebron University Hospital, Barcelona, ES

15:20 - 15:30    **Q&A and live discussion**

**14:15 - 15:30**    **Type: Proffered paper**    **Channel 2**  
**Title: Proffered Paper session 1**

14:15 - 14:16    **Live introduction**

14:16 - 14:26    **630 - Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: survival results of the UNICANCER-NeOPAL study**

S. Delaloge<sup>1</sup>, S. Dureau<sup>2</sup>, V. D'Hondt<sup>3</sup>, I. Desmoulins<sup>4</sup>, P.-E. Heudel<sup>5</sup>, F. Duhoux<sup>6</sup>, C. Levy<sup>7</sup>, F. Lerebours<sup>8</sup>, M.-A. Mouret-Reynier<sup>9</sup>, F. Dalenc<sup>10</sup>, J.-S. Frenel<sup>11</sup>, C. Jouannaud<sup>12</sup>, L. Venat-Bouvet<sup>13</sup>, S. Nguyen<sup>14</sup>, C. Callens<sup>15</sup>, D. Gentien<sup>2</sup>, H. Manduzio<sup>16</sup>, A. Vincent-Salomon<sup>15</sup>, J. Lemonnier<sup>16</sup>, P. Cottu<sup>15</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>Curie Institute, Paris, FR, <sup>3</sup>ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, <sup>4</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, <sup>7</sup>Centre François Baclesse, Caen, FR, <sup>8</sup>Hôpital René Huguenin - Institut Curie, St. Cloud, FR, <sup>9</sup>Centre Jean-Perrin, Clermont Ferrand, FR, <sup>10</sup>Centre Claudius-Regaud, Toulouse, FR, <sup>11</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>12</sup>Institut de Cancérologie Jean-Godinot, Reims, FR, <sup>13</sup>CHU Limoges, Limoges, FR, <sup>14</sup>Centre Hospitalier de Pau, Pau, FR, <sup>15</sup>Institut Curie, Paris, FR, <sup>16</sup>UNICANCER, Paris, FR

- 14:26 - 14:36 **910 - Pooled analysis of patient (pt)-reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: additional results and key subgroup findings**
- P.A. Fasching<sup>1</sup>, A. Bardia<sup>2</sup>, A. Nusch<sup>3</sup>, G. Jerusalem<sup>4</sup>, A. Chan<sup>5</sup>, N. El Saghir<sup>6</sup>, E. Alba Conejo<sup>7</sup>, S.-A. Im<sup>8</sup>, W. Janni<sup>9</sup>, D. Chandiwana<sup>10</sup>, B. Lanoue<sup>11</sup>, A. Thuerigen<sup>12</sup>, E. Gu<sup>13</sup>, N. Harbeck<sup>14</sup>, <sup>1</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>2</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>3</sup>Onkologische Praxis Velbert, Velbert, DE, <sup>4</sup>CHU Liège and Liège University, Liège, BE, <sup>5</sup>Breast Cancer Research Centre BCRC - WA, Nedlands, AU, <sup>6</sup>AUBMC - American University of Beirut Medical Center, Beirut, LB, <sup>7</sup>Hospital Universitario Virgen de la Victoria, Málaga, ES, <sup>8</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>9</sup>Ulm Medical University, Ulm, DE, <sup>10</sup>Novartis, East Hanover, US, <sup>11</sup>Novartis Pharmaceuticals Corp., East Hanover, US, <sup>12</sup>Novartis Pharma AG, Basel, CH, <sup>13</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>14</sup>Ludwig Maximilians University - Grosshadern, Munich, DE
- 14:36 - 14:46 **Invited Discussant 630 and 910**
- 14:46 - 14:53 **Q&A and live discussion**
- 14:53 - 15:03 **10 - Detection of homologous recombination repair deficiency (HRD) in treatment-naïve early triple negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests**
- V. Serra Elizalde<sup>1</sup>, A. Llop-Guevara<sup>2</sup>, A. Pearson<sup>3</sup>, C. Cruz<sup>2</sup>, M. Castroviejo-Bermejo<sup>2</sup>, N. Chopra<sup>3</sup>, H. Tovey<sup>3</sup>, C. Toms<sup>3</sup>, D. Kriplani<sup>3</sup>, H. Gevensleben<sup>3</sup>, R. Roylance<sup>4</sup>, S. Chan<sup>5</sup>, A. Tutt<sup>6</sup>, A. Skene<sup>7</sup>, A. Evans<sup>8</sup>, H. Davies<sup>9</sup>, J. Bliss<sup>10</sup>, S. Nik-Zainal<sup>11</sup>, J. Balmaña<sup>2</sup>, N. Turner<sup>12</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>3</sup>The Institute of Cancer Research, London, GB, <sup>4</sup>UCLH - University College London Hospitals NHS Foundation Trust, London, GB, <sup>5</sup>Nottingham University Hospital Trust, Nottingham, GB, <sup>6</sup>Guy's Hospital, King's College London, London, GB, <sup>7</sup>Royal Bournemouth Hospital, Bournemouth, GB, <sup>8</sup>Poole Hospital NHS Foundation Trust, Poole, GB, <sup>9</sup>University of Cambridge, Cambridge, GB, <sup>10</sup>ICR - Institute of Cancer Research, London, GB, <sup>11</sup>Addenbrooke's Treatment Centre, Cambridge, GB, <sup>12</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 15:03 - 15:13 **20 - Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial**
- A. Llop-Guevara<sup>1</sup>, V. Vladimirova<sup>2</sup>, A. Schneeweiss<sup>3</sup>, G. Villacampa<sup>1</sup>, T. Karn<sup>4</sup>, D.-M. Zahm<sup>5</sup>, A. Herencia-Ropero<sup>1</sup>, P. Jank<sup>6</sup>, M. Van Mackelenbergh<sup>7</sup>, P.A. Fasching<sup>8</sup>, F. Marmé<sup>9</sup>, E. Stickeler<sup>10</sup>, C. Schem<sup>11</sup>, R. Dienstmann<sup>1</sup>, S. Florian<sup>12</sup>, V. Nekljudova<sup>13</sup>, J. Balmaña<sup>1</sup>, C. Denkert<sup>14</sup>, S. Loibl<sup>15</sup>, V. Serra<sup>1</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>2</sup>GBG, Neu-Isenburg, DE, <sup>3</sup>Nationales Centrum für Tumorerkrankungen, Heidelberg, DE, <sup>4</sup>Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, <sup>5</sup>SRH Wald-Klinikum Gera, Gera, DE, <sup>6</sup>Philipps-Universität Marburg, Marburg, DE, <sup>7</sup>Universitätsklinikum Schleswig-Holstein, Kiel, DE,

<sup>8</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>9</sup>UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>10</sup>Uniklinik RWTH Aachen, Aachen, DE, <sup>11</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>12</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>13</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>14</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>15</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

15:13 - 15:23 **Invited Discussant 10 and 20**

15:23 - 15:30 **Q&A and live discussion**

**14:15 - 15:30 Type: Young oncologist session  
Title: YO Boxing session**

**Channel 3**

14:15 - 14:20 **Live introduction**

14:20 - 14:35 **Germline testing beyond BRCA: Do we need it? YES**

14:35 - 14:50 **Germline testing beyond BRCA: Do we need it? NO**

14:50 - 15:05 **Should all breast cancer patients receiving AI be treated with bone-modifying agents regardless of age and baseline T-score? YES**

15:05 - 15:20 **Should all breast cancer patients receiving AI be treated with bone-modifying agents regardless of age and baseline T-score? NO**

15:20 - 15:30 **Q&A and live discussion**

<b>15:45 - 17:00</b>	<b>Type: Multidisciplinary tumour board</b> <b>Title: Neoadjuvant/ adjuvant treatment of HER2+</b> Chair(s): David Cameron, GB; Martine Piccart, BE	<b>Channel 1</b>
15:45 - 15:50	<b>Live introduction</b>	
15:50 - 16:05	<b>Evaluation of HER2 status: What else needs to be known</b> <u>A. Vincent-Salomon</u> , Institut Curie, Paris, FR	
16:05 - 16:20	<b>Can we cure oligometastatic HER2+ disease?</b> <u>D. Cameron</u> , Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB	
16:20 - 16:35	<b>Should we maximise HER2 blockade for triple positive disease?</b> <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
16:35 - 16:50	<b>Surgery in the time of pathological complete responses: How to adapt to better systemic therapy?</b> <u>H.-B. Lee</u> , Seoul National University Hospital, Seoul, KR	
16:50 - 17:00	<b>Q&amp;A and live discussion</b>	

<b>15:45 - 17:00</b>	<b>Type: Educational session</b> <b>Title: Impact of ethnicity-based differences in breast cancer</b> Chair(s): Seock-Ah Im, KR; Ellen Copson, GB	<b>Channel 2</b>
15:45 - 15:50	<b>Live introduction</b>	
15:50 - 16:05	<b>Ethnicity, clinico-pathologic difference and outcome of young breast cancer patients</b> <u>E. Copson</u> , Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB	
16:05 - 16:20	<b>Impact of ethnicity on efficacy and toxicity of cyclin d kinase 4/6 inhibitors with endocrine therapy</b> <u>S.-A. Im</u> , SNUH - Seoul National University Hospital, Seoul, KR	
16:20 - 16:35	<b>Pharmacokinetic differences and ethnic variability in tolerance of cytotoxic drugs</b> <u>R. Danesi</u> , University of Pisa - DAM, Pisa, IT	
16:35 - 16:50	<b>Ethnic differences in hereditary breast cancer focusing on BRCAmt in PARPi era</b> <u>Y.H. Park</u> , Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR	
16:50 - 17:00	<b>Q&amp;A and live discussion</b>	

**15:45 - 17:00**    **Type: Educational session**    **Channel 3**  
**Title: Optimal sequence in metastatic ER+ breast cancer**  
 Chair(s): Nadia Harbeck, DE; Fatima Cardoso, PT

15:45 - 15:50    **Live introduction**

15:50 - 16:05    **Use of biomarkers to guide treatment selection**  
M. Liu, Mayo Clinic, Rochester, US

16:05 - 16:20    **CDK 4/6i: The established first-line standard?**  
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

16:20 - 16:35    **Progression after CDK 4/6i: How to sequence approved options**  
F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

16:35 - 16:50    **Progression after CDK 4/6i: New kids on the block**  
P. Aftimos, Institute Jules Bordet, Brussels, BE

16:50 - 17:00    **Q&A and live discussion**

**17:15 - 18:30**    **Type: Proffered paper**    **Channel 1**  
**Title: Best abstracts**

17:15 - 17:16    **Live introduction**

17:16 - 17:28    **410 - Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHER randomised trial.**  
P.F. Conte<sup>1</sup>, A. Frassoldati<sup>2</sup>, G. Bisagni<sup>3</sup>, A. Brandes<sup>4</sup>, M. Donadio<sup>5</sup>, O. Garrone<sup>6</sup>, F. Piacentini<sup>7</sup>, L. Cavanna<sup>8</sup>, F. Giotta<sup>9</sup>, M. Aieta<sup>10</sup>, V. Gebbia<sup>11</sup>, A. Musolino<sup>12</sup>, A. Ferro<sup>13</sup>, S. Danese<sup>14</sup>, C. Zamagni<sup>15</sup>, O. Nanni<sup>16</sup>, M.V. Dieci<sup>17</sup>, R. Vicini<sup>18</sup>, S. Balduzzi<sup>19</sup>, V. Guarneri<sup>20</sup>, <sup>1</sup>university of padova, padova, IT, <sup>2</sup>Azienda Ospedaliera di Ferrara St. Anna, Ferrara, IT, <sup>3</sup>Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>4</sup>Ospedale Bellaria, Bologna, IT, <sup>5</sup>AOU Città della Salute e della Scienza Torino, Torino, IT, <sup>6</sup>Azienda Ospedaliera St. Croce e Carle, Cuneo, IT, <sup>7</sup>Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, <sup>8</sup>Area Ospedaliera di Piacenza - Ospedale Guglielmo da Saliceto - AUSL Piacenza, Piacenza, IT, <sup>9</sup>Istituto Oncologico Bari, Bari, IT, <sup>10</sup>Centro di Riferimento Oncologico Basilicata IRCCS, Rionero in Vulture, IT, <sup>11</sup>Casa di Cura La Maddalena Dipartimento Oncologico di III livello, Palermo, IT, <sup>12</sup>Azienda Ospedaliera di Parma, Parma, IT, <sup>13</sup>Ospedale Santa Chiara - APSS, Trento, IT, <sup>14</sup>S Anna Hospital, torino, IT, <sup>15</sup>AOU Policlinico S. Orsola-Malpighi, F.Addarii, Bologna, IT, <sup>16</sup>Istituto Tumori della Romagna I.R.S.T., Meldola, IT, <sup>17</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>18</sup>azienda ospedaliero universitaria di modena, modena, IT, <sup>19</sup>universita di modena e reggio emilia, modena, IT, <sup>20</sup>Istituto Oncologico

Veneto IRCCS, Padova, IT

- 17:28 - 17:40 **420 - Biomarker analysis from KAITLIN, a randomised phase 3 study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)**
- O. Metzger<sup>1</sup>, C. Lambertini<sup>2</sup>, I. Krop<sup>3</sup>, G. Lewis Phillips<sup>4</sup>, C. Perou<sup>5</sup>, F. Symmans<sup>6</sup>, I. Melero<sup>7</sup>, N. Harbeck<sup>8</sup>, E. Winer<sup>9</sup>, S.-A. Im<sup>10</sup>, C. Barrios<sup>11</sup>, H. Bonnefoi<sup>12</sup>, J. Gralow<sup>13</sup>, P. Ellis<sup>14</sup>, L. Gianni<sup>15</sup>, M. Toi<sup>16</sup>, S. Swain<sup>17</sup>, T. Boulet<sup>2</sup>, C. Song<sup>4</sup>, S. De Haas<sup>18</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>F. Hoffmann-La Roche Ltd., Basel, CH, <sup>3</sup>Dana Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>4</sup>Genentech, Inc., South San Francisco, US, <sup>5</sup>University of North Carolina at Chapel Hill, Chapel Hill, US, <sup>6</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>7</sup>Clinica Universitaria de Navarra, Pamplona, ES, <sup>8</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>9</sup>Harvard Medical School, Boston, US, <sup>10</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>11</sup>Centro de Hematologia Oncologia E Transplante, Porto Alegre, BR, <sup>12</sup>Institute Bergonié, Bordeaux, FR, <sup>13</sup>University of Washington Seattle Cancer Care Alliance, Seattle, US, <sup>14</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>15</sup>Fondazione Michelangelo, Milano, IT, <sup>16</sup>Kyoto University-Graduate school of medicine, Kyoto, JP, <sup>17</sup>Georgetown University Medical Center, Washington, US, <sup>18</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH
- 17:40 - 17:52 **430 - Pertuzumab/Trastuzumab in Early Stage HER2-positive Breast Cancer: 5-year and Final Analysis of the BERENICE Trial**
- C. Dang<sup>1</sup>, M. Ewer<sup>2</sup>, S. Delaloge<sup>3</sup>, J.-M. Ferrero<sup>4</sup>, R. Colomer<sup>5</sup>, L. De La Cruz Merino<sup>6</sup>, K. Dadswell<sup>7</sup>, M. Verrill<sup>8</sup>, D. Eiger<sup>9</sup>, S. Sarkar<sup>7</sup>, S. De Haas<sup>10</sup>, E. Restuccia<sup>11</sup>, S. Swain<sup>12</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>2</sup>University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Institut Gustave Roussy, Paris, FR, <sup>4</sup>Centre Antoine Lacassagne, Nice, FR, <sup>5</sup>Division of Medical Oncology, Madrid, ES, <sup>6</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>7</sup>Roche Products Limited, Welwyn Garden City, GB, <sup>8</sup>The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, <sup>9</sup>F. Hoffmann- La Roche AG, Basel, CH, <sup>10</sup>F. Hoffmann-La Roche AG - Switzerland, Basel, CH, <sup>11</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>12</sup>Georgetown University Medical Center, Washington, US
- 17:52 - 18:07 **Invited Discussant 410, 420 and 430**
- 18:07 - 18:27 **Q&A and live discussion**

08.05.2021

**12:00 - 12:30**    **Type: Keynote**    **Channel 1**  
**Title: Keynote 2**

12:00 - 12:05    **Introduction by the Chair**

12:05 - 12:30    **Title to be defined**

**12:45 - 14:00**    **Type: Educational session**    **Channel 1**  
**Title: Immunotherapy in metastatic breast cancer**  
Chair(s): Marleen Kok, NL; Sherene Loi, AU

12:45 - 12:50    **Live introduction**

12:50 - 13:10    **First-line chemo-IO for mTNBC**  
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

13:10 - 13:30    **Future of PD-1 blockade for ER+ and HER2+ mBC**  
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

13:30 - 13:50    **Potential of IO-IO combinations for mBC**  
M. Kok, Netherlands Cancer Institute, Amsterdam, NL

13:50 - 14:00    **Q&A and live discussion**

**12:45 - 14:00**    **Type: Mini oral**    **Channel 2**  
**Title: Mini Oral session 2**

12:45 - 12:46    **Live introduction**

12:46 - 12:51    **One LBA TBC**

12:51 - 12:56    **95MO - Characteristics of patients with brain metastases from HER2-positive breast cancer**

E. Laakmann<sup>1</sup>, I. Witzel<sup>2</sup>, T. Neunhöffer<sup>3</sup>, T.-W. Park-Simon<sup>4</sup>, R. Weide<sup>5</sup>, K. Riecke<sup>1</sup>, A. Polasik<sup>6</sup>, M. Schmidt<sup>7</sup>, J. Puppe<sup>8</sup>, C. Mundhenke<sup>9</sup>, K. Lübke<sup>10</sup>, T. Hesse<sup>11</sup>, M. Thill<sup>12</sup>, D.-M. Zahm<sup>13</sup>, C. Denkert<sup>14</sup>, T. Fehm<sup>15</sup>, V. Nekljudova<sup>16</sup>, J. Rey<sup>16</sup>, S. Loibl<sup>17</sup>, V. Mueller<sup>2</sup>,  
1Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, 2UKE Universitätsklinikum

Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>3</sup>HELIOS Dr. Host Schmidt Kliniken, Wiesbaden, DE, <sup>4</sup>Medizinische Hochschule Hannover (MHH), Hannover, DE, <sup>5</sup>Praxis für Hämatologie und Onkologie Koblenz, Koblenz, DE, <sup>6</sup>Universitätsklinikum Ulm, Ulm, DE, <sup>7</sup>Universitätsmedizin Mainz, Mainz, DE, <sup>8</sup>Gynecology and Obstetrics University Hospital of Cologne, Köln, DE, <sup>9</sup>Klinikum Bayreuth GmbH, Bayreuth, DE, <sup>10</sup>Frauenklinik Hannover, Hannover, DE, <sup>11</sup>Agaplesion Diakonieklinikum, Rotenburg, DE, <sup>12</sup>Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE, <sup>13</sup>SRH Wald-Klinikum Gera, Gera, DE, <sup>14</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>15</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>16</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>17</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

12:56 - 13:01 **4MO - HER2-low breast cancer: evolution from primary breast cancer to relapse.**

F. Miglietta<sup>1</sup>, G. Griguolo<sup>2</sup>, M. Bottosso<sup>2</sup>, T. Giarratano<sup>2</sup>, M. Lo Mele<sup>3</sup>, M. Fassan<sup>1</sup>, M. Cacciatore<sup>4</sup>, E. Genovesi<sup>1</sup>, D. De Bartolo<sup>1</sup>, G. Vernaci<sup>5</sup>, P.F. Conte<sup>6</sup>, V. Guarneri<sup>5</sup>, M.V. Dieci<sup>2</sup>, <sup>1</sup>University of Padova, Padova, IT, <sup>2</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>3</sup>University Hospital of Padova, Padova, IT, <sup>4</sup>Treviso General Hospital, Treviso, IT, <sup>5</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>university of padova, padova, IT

13:01 - 13:13 **Invited Discussant one LBA TBC, 95MO and 4MO**

13:13 - 13:26 **Q&A and live discussion**

13:26 - 13:31 **One LBA TBC**

13:31 - 13:36 **96MO - A Risk Analysis of Alpelisib (ALP)-Induced Hyperglycemia (HG) Using Baseline Factors in Patients (pts) With Advanced Solid Tumors and Breast Cancer (BC): A Pooled Analysis of X2101 and SOLAR-1**

J. Rodon<sup>1</sup>, D. Demanse<sup>2</sup>, H. Rugo<sup>3</sup>, F. André<sup>4</sup>, F. Janku<sup>1</sup>, I. Mayer<sup>5</sup>, H. Burris<sup>6</sup>, R. Simo<sup>7</sup>, A. Farooki<sup>8</sup>, H. Hu<sup>9</sup>, I. Lorenzo<sup>10</sup>, C. Quadt<sup>11</sup>, D. Juric<sup>12</sup>, <sup>1</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>Novartis Pharma AG, Basel, CH, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Vanderbilt-Ingram Cancer Center, Nashville, US, <sup>6</sup>Sarah Cannon Research Institute, Nashville, US, <sup>7</sup>Autonomous University of Barcelona, Barcelona, ES, <sup>8</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>9</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>10</sup>Novartis Farmacéutica SA, Madrid, ES, <sup>11</sup>Novartis International AG - Basel, Basel, CH, <sup>12</sup>Massachusetts General Hospital Cancer Center, Boston, US

13:36 - 13:46 **Invited Discussant one LBA TBC and 96MO**

13:46 - 13:58 **Q&A and live discussion**

**12:45 - 14:00** **Type: Young oncologist session** **Channel 3**  
**Title: YOC Forum - The future of academic research in oncology: Is there a role for young oncologists?**

12:45 - 12:47 **Live introduction**

12:47 - 13:02 **Challenges and opportunities: Key rules to get involved**

13:02 - 13:17 **The crucial role of mentorship and fellowships**

13:17 - 13:32 **Why join a large cooperative group? Let's make a BIG example**

13:32 - 13:47 **Tips and tricks to get your idea funded by pharma**

13:47 - 13:57 **Q&A and live discussion**

**14:15 - 14:45** **Type: Keynote** **Channel 1**  
**Title: Cutting-edge surgical research**  
Chair(s): Sung-Bae Kim, KR

14:15 - 14:20 **Introduction by the Chair**  
S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

14:20 - 14:45 **Cutting-edge surgical research**  
M. Toi, Kyoto University-Graduate school of medicine, Kyoto, JP

<b>15:00 - 16:15</b>	<b>Type: Educational session</b> <b>Title: Optimizing the management of premenopausal women with early breast cancer</b> Chair(s): Lucia Del Mastro, IT; Olivia Pagani, CH	<b>Channel 1</b>
15:00 - 15:05	<b>Live introduction</b>	
15:05 - 15:20	<b>Optimal adjuvant/neoadjuvant chemotherapy in triple negative subtype with or without gBRCA mutation</b> <u>S.-B. Kim</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
15:20 - 15:35	<b>Adjuvant chemotherapy in hormone-receptor positive tumours: Who to treat and which regimen?</b> <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, FR	
15:35 - 15:50	<b>Type and duration of endocrine therapy in hormone receptor positive tumours</b> <u>O. Pagani</u> , HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH	
15:50 - 16:05	<b>Preserving fertility in young patients</b> <u>L. Del Mastro</u> , IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT	
16:05 - 16:15	<b>Q&amp;A and live discussion</b>	

<b>15:00 - 16:15</b>	<b>Type: Educational session</b> <b>Title: Brain mets management in HER2+ and triple negative breast cancer</b> Chair(s): Yen-Shen Lu, TW; Volkmar Mueller, DE	<b>Channel 2</b>
15:00 - 15:05	<b>Live introduction</b>	
15:05 - 15:20	<b>Multidisciplinary management of breast cancer brain metastases</b> <u>J. Jung</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
15:20 - 15:35	<b>HER2 targeting agents for treatment of HER2+ breast cancer with brain mets</b> <u>V. Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
15:35 - 15:50	<b>Anti-angiogenesis therapy for breast cancer with brain or leptomeningeal mets</b> <u>Y.-S. Lu</u> , NTUH - National Taiwan University Hospital, Taipei City, TW	
15:50 - 16:05	<b>Emerging treatments for breast cancer with brain metastases</b> <u>A. Awada</u> , Institute Jules Bordet, Brussels, BE	
16:05 - 16:15	<b>Q&amp;A and live discussion</b>	

<b>15:00 - 16:15</b>	<b>Type: Educational session</b> <b>Title: Testing recommendation in breast cancer</b> Chair(s): Frederique Penault-Llorca, FR	<b>Channel 3</b>
15:00 - 15:05	<b>Live introduction</b>	
15:05 - 15:20	<b>State of art for luminal eBC: Ki67 and/or prognostic gene expression signatures?</b> <u>G. Viale</u> , Istituto Europeo di Oncologia, Milan, IT	
15:20 - 15:35	<b>Immunohistochemistry: The new IHC “low” categories (ER, HER2....) and androgen receptor testing</b> <u>C. Denkert</u> , Uniklinikum Giessen und Marburg, Marburg, DE	
15:35 - 15:50	<b>Biomarkers for immunotherapy (PD-L1, TILs, IA...): How and when?</b> <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
15:50 - 16:05	<b>Molecular testing algorithms for metastatic BC</b> <u>F. Rojo</u> , University Hospital Fundacion Jimenez Diaz, Madrid, ES	
16:05 - 16:15	<b>Q&amp;A and live discussion</b>	

**16:30 - 17:45** **Type: Educational session** **Channel 1**  
**Title: Adjuvant treatment early HER+ in breast cancer**  
 Chair(s): Sara Tolaney, US; E.G. Elisabeth de Vries, NL

16:30 - 16:35 **Live introduction**

16:35 - 16:50 **Current standard approaches for early stage HER2+ disease**  
V. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

16:50 - 17:05 **How low should we go? Treatment for stage I HER2+ disease**  
S. Tolaney, Dana Farber Cancer Institute, Boston, US

17:05 - 17:20 **Can imaging help tailor preoperative HER2-directed therapy?**  
E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

17:20 - 17:35 **The path ahead: De-escalating and escalating care for early stage HER2+ disease**  
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

17:35 - 17:45 **Q&A and live discussion**

**16:30 - 17:45** **Type: Educational session** **Channel 3**  
**Title: Early drug development in breast cancer**  
 Chair(s): Ana Mafalda Antunes De Melo e Oliveira, ES; Erika Hamilton, US

16:30 - 16:35 **Live introduction**

16:35 - 16:50 **Epigenetic modulating drugs: Are we hitting the target?**  
S. Minucci, European Institute of Oncology, Milan, IT

16:50 - 17:05 **Immunotherapy combos in TNBC**  
A.M. Antunes De Melo E Oliveira, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

17:05 - 17:20 **Next wave of ADCs: New targets, new drugs, new indications**  
V. Boni, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES